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Abstract 
Runx1 is a master regulator of hematopoiesis, required for the initiation of definitive 
hematopoiesis in the embryo and essential for appropriate differentiation of many 
hematopoietic lineages in the adult. The roles of Runx1 in normal hematopoiesis are 
juxtaposed with the high frequency of Runx1 mutations and translocations in leukemia.  
Leukemia associated Runx1 mutations that retain DNA-binding ability have truncations 
or frame shifts that lose C-terminal domains. These domains are important for subnuclear 
localization of Runx1 and protein interactions with co-factors. The majority of leukemia 
associated Runx1 translocations also replace the C-terminus of Runx1 with chimeric 
fusion proteins. The common loss of Runx1 C-terminal domains in hematopoietic 
diseases suggests a possible common mechanism. We developed a panel of mutations to 
test the functions of these domains in vitro, and then developed mouse models to examine 
the consequences of losing Runx1 C-terminal domains on hematopoietic development 
and leukemogenesis in vivo. 
 
We previously observed that overexpression of a subnuclear targeting defective mutant of 
Runx1 in a myeloid progenitor cell line blocks differentiation. Gene expression analysis 
before differentiation was initiated revealed that the mutant Runx1 was already 
deregulating genes important for maturation. Furthermore, promoters of the suppressed 
v 
 
genes were enriched for binding sites of known Runx1 co-factors, indicating a non-DNA-
binding role for the mutant Runx1.  
 
To investigate the in vivo function of Runx1 C-terminal domains, we generated two 
knock-in mouse models; a C-terminal truncation, Runx1Q307X, and a point mutant in the 
subnuclear targeting domain, Runx1HTY350-352AAA. Embryos homozygous for Runx1Q307X 
phenocopy a complete Runx1 null and die in utero from central nervous system 
hemorrhage and lack of definitive hematopoiesis. Embryos homozygous for the point 
mutation Runx1HTY350-352AAA bypass embryonic lethality, but have hypomorphic Runx1 
function. Runx1HTY350-352AAA results in defective growth control of hematopoietic 
progenitors, deregulation of B-lymphoid and myeloid lineages, as well as maturation 
delays in megakaryocytic and erythroid development.  
 
Runx1 localizes to subnuclear domains to scaffold regulatory machinery for control of 
gene expression. This work supports the role of transcription factors interacting with 
nuclear architecture for greater biological control, and shows how even subtle alterations 
in that ability could have profound effects on normal biological function and gene 
regulation. 
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Chapter 1: General Introduction 
Runx Proteins 
Runx1, Runx2 and Runx3 are the three DNA-binding alpha subunits of the Core Binding 
Factor (CBF) heterodimeric transcription factor. The shared beta subunit (CBFbeta) 
protects the alpha subunit from degradation and greatly increases the DNA-binding 
affinity for the complex, while not binding DNA itself.1,2 The expression of Runx factors 
is tissue specific, while they all bind the same consensus sequence (Figure 1). The three 
alpha subunits historically have several different names from the manners in which they 
were isolated. The consensus binding sequence is contained within many viral enhancers 
and earned the Runx proteins the names Polyomavirus Enhancer Binding Protein 2 
(PEBP2)3 and CBF from the core murine leukemia virus enhancer.4 Runx1 was originally 
named Acute Myeloid Leukemia 1 (AML1) when it was identified as the target on 
chromosome 21 of the leukemic (8;21) translocation.5 Runx2 is important in bone 
biology, which earned the Runx proteins the names Nuclear Matrix Protein 2 (NMP2)6, 
Osteoblast-specific Complex (OBSC)7 and Osteoblast-specific Factor 2 (OSF2).8 The 
DNA-binding domain of all 3 Runx factors is homologous to the Drosophila protein 
Runt. Therefore, the term Runt-related transcription factor (RUNX) has been formally 
adopted by researchers studying all three of the CBF alpha subunits.9 
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All three Runx factors are lineage determining transcription factors. Runx1 is essential 
for embryonic hematopoiesis.10 Runx2 is required for ossification in bone.11,12 Runx3 is 
implicated in gastric and neuronal development.13,14 All three Runx factors contain 
several highly conserved domains (Figure 1), including the DNA-binding Runt homology 
domain (RHD) at the N-terminus15, and a nuclear matrix targeting signal (NMTS) 
responsible for subnuclear targeting at the C-terminus.16 The RHD dimerizes with 
CBFbeta and binds the consensus DNA sequence TGTGGT. Gene regulation is carried 
out through protein-protein interactions with co-factors, mediated by additional 
domains.17-23 The NMTS in Runx proteins is a 30-40 amino acid sequence that targets 
Runx to distinct subnuclear foci, associated with transcriptional activity.24,25 Runx factors 
are thought to anchor to the nuclear matrix and act as a scaffold, associating regions of 
DNA with other factors via its many interaction domains.26,27 Playing a functional role in 
the three dimensional architecture of the nucleus dramatically increases the potential 
mechanisms for Runx factors to regulate gene expression.28,29 
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Figure 1: Schematic of Runx transcription factors 
All three Runx transcription factors have a conserved Runt Homology Domain (RHD) which 
dimerizes with CBFbeta and binds the consensus DNA motif.30 The RHD also contains the 
Nuclear Localization Signal (NLS) at the C-terminal end. All three Runx proteins also have a 
conserved Nuclear Matrix Targeting Signal (NMTS) and several conserved co-factor interaction 
domains, including transactivation domains and the VWRPY domain critical for association with 
the Groucho/TLE co-repressor. Shown are the amino acid lengths for human Runx1, Runx2 and 
Runx3. The amino acid lengths of the mouse proteins are 451, 513, and 410, respectively. 
CBFbeta increases the DNA-binding ability of each Runx factor by forming a heterodimer via its 
dimerization domain and the RHD. Both human and mouse CBFbeta contain 187 amino acids. 
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Nuclear Architecture 
The nuclear matrix is a ribonucleoprotein network extending from the inner nuclear 
envelope throughout the nucleus.31 Electron microscopy, with much higher resolution 
than light microscopy and better staining techniques, allowed the observation of a highly 
structured nucleus with many substructures that contained little or no DNA. The nuclear 
matrix is functionally defined as the non-chromatin structures of the nucleus observed 
under the electron microscope in unextracted cells.31 Release of the ribonucleoprotein 
particles would not occur with only removal of the nuclear envelope or treatment with 
DNase, but required digestion with ribonucleases.32 This indicated that the nuclear matrix 
contained structural RNA. Early studies of the nuclear matrix found an RNase resistant 
scaffolding made up of protein fibers connected to nuclear lamina.33 The current model 
states the nuclear matrix is a network of branched filaments that connect to the nuclear 
lamina.34-36 Other components of the nuclear matrix have either direct or indirect 
interactions with these filaments.31 
 
The nuclear matrix serves important roles in DNA replication and transcription. Newly 
synthesized DNA and replication factories are attached to the nuclear matrix.37-39 
Transcription machinery, RNA polymerase II, splicing factories and many transcription 
factors also remain in the nuclear matrix after DNase digestion.31,40 In addition to 
tethering important complexes involved in gene expression, over 400 proteins are 
associated with the nuclear matrix.41 Some of these proteins, like the Runx transcription 
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factors and ALL1, act as scaffolds to organize other regulatory factors.42,43 Associating 
chromatin remodeling enzymes, transcription factors and signaling molecules all together 
at the same three-dimensional space as DNA allows for combinatorial control of gene 
expression, greatly increasing potential regulation by these transcription factors.44     
   
Most transcription factors have a nuclear localization signal (NLS) that marks them for 
translocation into the nucleus. Once inside the nucleus, a DNA binding domain 
determines its sequence specificity and a nuclear matrix targeting signal (NMTS) is 
required for proper interactions within the nuclear matrix. The first transcription factors 
identified with a NMTS were Runx1 and Runx2.25 The Runx NMTS targets it to matrix 
associated transcriptional domains.24 Currently, many transcription factors have an 
identified NMTS, including steroid receptors, PIT1, YY1, SATB1, and even the leukemia 
associated Runx1/ETO, which has distinct subnuclear targeting from Runx1.45-51  
 
Cancer cells exhibit massive gene deregulation and profound morphological changes in 
their nuclei.52,53 Several aspects of the nuclear architecture are altered in the cancer cell, 
suggesting a functional connection between nuclear organization and gene expression.44 
Nuclear architecture assembles DNA and proteins in three-dimensional space and is 
important for many biological functions (Figure 2). These complex spatial organizations 
of the genome with factors that influence its expression are very important for 
appropriate gene regulation, and are often perturbed in disease.16,26-29,54-57  
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Figure 2: Nuclear architecture functionally links regulatory information. 
Nuclear architecture organizes regulatory signals. Immunofluorescence microscopy  
reveals distinct subnuclear distribution of important processes, including DNA replication and 
repair, apoptosis, chromatin remodeling, transcriptional control and RNA processing. All of these 
domains are associated with the nuclear matrix.  
 
 
 
Stein et al., Trends in Cell Biology 2003; 13(11):584-92 
Reproduced with permission 
License Number: 2895480524553 
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Runx1 in Normal and Malignant Hematopoiesis 
Runx1 plays several important roles throughout normal hematopoiesis. It is required for 
the initial emergence of the hematopoietic stem cell (HSC) from the hemogenic 
endothelium in the embryo.10,58,59 Without Runx1 function, embryos die in utero at 
embryonic day 12.5, from central nervous system hemorrhage and complete lack of 
definitive hematopoiesis.10,58,59 In adults, Runx1 is still required for growth control of 
hematopoietic progenitors and may play a role in maintaining long term repopulation 
potential.60-62 In addition to the stem cell, Runx1 is important in regulating the 
differentiation of many mature blood lineages (Figure 3).63  
 
Runx1 contributes to B and T-lymphoid development. Abrogation of Runx1 expression64-
66, or expression of leukemic dominant negative inhibitors of Runx1 function67, impede 
B-lymphopoiesis. Runx factors are expressed in developing T-cells68 and precise control 
of Runx1 expression is critical for their maturation. Removal of the C-terminal VWRPY 
domain of Runx1 results in reduced CD8 single positive T-cells.69 Runx3 mediated 
downregulation of Runx1 is required T-cell progenitors to mature through CD4/CD8 
double negative stages70 and to silence CD4 to transition from double positive to CD8 
single positive cells.71,72 Thus, Runx1 plays several distinct roles throughout 
lymphopoiesis. 
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Figure 3: Definitive hematopoiesis. 
Runx1 has critical roles in the initial emergence of the hematopoietic stem cell (HSC) from the 
hemogenic endothelium. In addition,  Runx1 is important for differentiation into multi-potent 
progenitors (MPP), common lymphoid progenitors (CLP), common myeloid progenitors (CMP), 
and further committed cell types in both lymphoid and myeloid hematopoietic lineages.  
 
Adapted from Larsson and Karlsson, Oncogene 2005; 24(37):5676-92  
Reproduced with permission   
License Number: 2895470995227 
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Megakaryocyte maturation requires Runx1 function.66 Runx1 controls expression of the 
thrombopoietin receptor, and many other genes critical for megakaryocyte 
development.73-76 Point mutations in Runx1 are responsible for familial platelet 
disorders77,78 and abrogated platelet production is a common finding in animal models 
with Runx1 mutations.63,79  
 
Runx1 is a key factor during myeloid development.79-81 Runx1 was initially cloned as the 
target on chromosome 21 of the myeloid leukemic (8;21) translocation.5 CSF1R, the 
receptor for myeloid growth factors M-CSF and GM-CSF is one of the most well 
characterized targets of Runx1 regulation.82-84 Runx1 also directly regulates the myeloid 
specific transcription factor PU.1 at the level transcription85 as well as interaction with 
co-factors.86 Disrupting Runx1 function in myeloid cells blocks differentiation and 
contributes to a transformed phenotype.87 There is a critical role for Runx1 during 
myelopoiesis, and disruption of Runx1 function can drive leukemogenesis. 
 
Runx1 and CBFbeta are the most common targets of mutation or translocation in human 
acute myeloid leukemias (AML).88,89 The (8;21) translocation is found in 12-15% of de 
novo adult AML and is a major contribution to secondary AML in patients who received 
cytotoxic chemotherapy.88-91 In addition to AML, Runx1 mutations are found in chronic 
myelomonocytic leukemia (CMML), myeloid dysplastic syndromes (MDS), refractory 
anemia with excess blasts (RAEB) and familial platelet disorder (FPD) which also have 
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predisposition toward AML.77,78,88,92-95 Disruption of Runx1 contributes to many types of 
hematopoietic disease. 
 
Leukemia associated point mutations of Runx1 are either missense mutations in the 
DNA-binding RHD, or truncations removing C-terminal domains including the NMTS.96 
RHD mutations cause dominant negative inhibition, or are hypomorphic depending on 
what degree of DNA-binding is maintained.97 CBFbeta greatly increases the DNA 
binding ability of Runx1 and reduction of CBFbeta dosage causes phenotypes similar to 
Runx1 ablation.98-101 The C-terminus of Runx1 does not contact DNA or CBFbeta, 
therefore the disease mechanism of C-terminal mutation must involve functions other 
than DNA-binding.   
 
The C-terminus of Runx1 contains many known co-factor interaction domains and the 
NMTS. The (8;21) translocation removes the NMTS and the chimeric fusion protein 
displays altered subnuclear targeting.49,51 NMTS mutants of Runx1 within myeloid cell 
lines disrupt subnuclear localization, alter gene transcription and affect a transformation 
like phenotype.87 These data suggest that loss of C-terminal domains of Runx1 in the 
disease associated mutations and translocations may represent a common disease 
mechanism. Greater understanding of these functional domains is required to understand 
how their loss contributes to disease. The following studies examine the functional roles 
of Runx1 C-terminal domains during normal hematopoiesis and leukemic development. 
11 
 
Expression of Runx1 mutations in hematopoietic cell lines and primary cells in vitro, 
followed by generation of a knock-in mouse models of Runx1 C-terminal truncation and 
a Runx1 C-terminal point mutation, revealed the contributions of distinct domains in 
Runx1 throughout its many roles in hematopoiesis. 
12 
 
Chapter 2: Runx1 C-Terminal Mutants Alter Growth Control and 
Differentiation in Hematopoietic Cells  
 
Runx1 is a key hematopoietic transcription factor required for definitive hematopoiesis 
and a frequent target of leukemia-related mutations and chromosomal translocations. 
Leukemia-associated mutations occur in the DNA-binding domain at the N-terminus, or 
within C-terminal domains responsible for subnuclear targeting and co-factor 
interactions. Fusion proteins generated from leukemia-related translocations often retain 
DNA binding activity, but display loss of subnuclear targeting and associated 
transactivation functions encoded by the C-terminus of the protein. We purpose that the 
common loss of Runx1 C-terminal domains observed in these mutants could be a 
common mechanism of disease progression. To define the precise functions of Runx1 C-
terminal domains we developed a panel of mutations and assessed their effects in 
hematopoietic cells.  
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Introduction 
Runx1 is a master regulator of hematopoiesis, required for the emergence of 
hematopoietic stem cells (HSC) and appropriate differentiation across hematopoietic 
lineages.10,79,80 Runx1 is also a frequent target of for mutation and translocations in 
leukemia and other hematopoietic disorders.77,78,92,93,95,102 Mutations observed in patients 
cluster either in the N-terminal DNA-binding Runt Homology Domain (RHD), or within 
the C-terminus.96 Leukemia-associated translocations often retain DNA-binding ability 
while replacing the C-terminal domains with chimeric fusion protein.88 The domains 
disrupted or lost are critical for co-factor interactions and appropriate subnuclear 
targeting of Runx1.19-21,25,103 The disease mechanism for DNA-binding mutations is 
presumably lack of transcription factor binding and therefore lack of gene regulation. For 
Runx1 C-terminal mutations the biological consequences are not always as straight 
forward.  
 
Loss of C-terminal functional domains is common among many leukemia-associated 
Runx1 mutations, therefore we hypothesize that loss of co-factor interaction and aberrant 
subnuclear targeting may be a common leukemic mechanism. To examine the roles of 
precise domains within the C-terminus, we developed a panel of Runx1 mutations. Using 
these mutations in several cellular contexts, we investigated the biological consequences 
of precise mutations within the C-terminus. 
14 
 
Materials and Methods 
Construction of the Runx1 mutant vectors 
Wildtype Runx1 in the pcDNA3.1/HISa mammalian expression vector104 or the pMSCV-
IRES-GFP (pMIG) retroviral expression vector105 was mutated by site directed 
mutagenesis using a QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, 
CA) with the primers shown in Table 1. 
 
 
 
Table 1: Runx1 mutagenesis primers 
The forward and reverse primers used to generate the Runx1 mutants in Figure 4 are shown.  All 
primers conformed to the recommended specifications for site directed mutagenesis: 25-45 bases 
in length, a minimum 40% GC and melting point above 78ºC. 
 
 
 
15 
 
Luciferase assays 
HeLa cells were transfected with Fugene 6 (Roche) following manufacturer’s 
instructions. Cells were plated at 200,000 cells per well of a 6-well plate, and 3 wells for 
each construct was transfected with 500 ng of GM-CSF promoter luciferase reporter 
(pGL3)103; 200 ng of pcDNA3.1/HISa (Invitrogen) empty vector, Runx1 wildtype, 
Runx1Q307X , Runx1Y352A, Runx1HTY350-352AAA or Runx1Y357A; and 5 ng pHRL-null 
promoter-less Renilla luciferase.106 Luciferase activity was measured 24 hours after 
transfection using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI 
Cat. No. E1960) in a Glomax Luminometer (Promega) with Glomax 1.6 software.  
 
IVTT protein expression 
In vitro transcription and translation (IVTT) of Runx1 wildtype, Runx1R174Q, Runx1Y352A, 
Runx1HTY350-352AAA, Runx1Y357A and Runx1Q307X was performed using the TNT Coupled 
Reticulocyte Lysate System (Promega) following the manufacturer’s instructions. 
Successful IVTT reactions were tested by Western blot. 2 uL of IVTT lysate was diluted 
into 30 uL direct lysis buffer (2% SDS, 2 M urea, 10% glycerol, 10 mM Tris-HCl [pH 
6.8], 0.002% bromophenol blue, 10 mM DTT, 1× Complete protease inhibitor [Roche], 
25 uM MG132 and 1 mM PMSF) and boiled for 5 min. The entire volume was 
electrophoresed in an 8% SDS-polyacrylamide gel, at 100V for 1.5 hours. Separated 
proteins were transferred to an Immobilon Membrane (Millipore, Billerica, MA) by 
semidry transfer for 30min at 10V. Membranes were blocked for at least 1 hour in 5% 
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nonfat dry milk in PBST (PBS with 0.1% Tween 20) and then probed for 1 hour with  
primary antibody diluted 1:1000  (AML1(RHD) [Oncogene Science]). After four 5 min 
washes with PBST, blots were incubated for 1 hour with goat anti-rabbit IgG-HRP 
secondary antibody diluted 1:4000, washed four times for 5 min in PBST and detected 
with ECL (Perkin-Elmer, Waltham, MA). 
 
Electrophoretic Mobility Shift Assay (EMSA)  
Runx consensus oligonucleotide 5’-CGA GTA TTG TGG TTA ATA CG-3’ was end 
labeled as described previously.107,108 Upper strands of the oligonucleotides were labeled 
with 32P for 1 hour at 37°C in a 50 uL volume using T4 Polynucleotide Kinase (New 
England BioLabs, Beverly, MA) following manufacturer’s instructions. The reaction was 
stopped by heat inactivation at 65°C for 1 hour. Annealing was performed by addition of 
a twofold excess amount of bottom strand followed by boiling for 5 min and slow cooling 
to room temperature. Unincorporated nucleotides were removed with a quick-spin G 25 
Sephadex column (Roche Molecular Biochemicals, Indianapolis, IN) according to the 
manufacturer's instructions. 2 uL of IVTT lysate for Runx1 wildtype, Runx1R174Q, 
Runx1Y352A, Runx1HTY350-352AAA, Runx1Y357A or Runx1Q307X were used in the binding 
reaction. Reaction mixtures were prepared using 50 fmol of probe, 50 mM KCl, 1 mM 
magnesium chloride, 1 mM DTT, 2 mM sodium fluoride, 2 mM sodium vanadate, 10% 
glycerol, 2 ug of poly(dI-dC)•poly(dI-dC), and DNA binding reactions were carried out 
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at 25˚C for 20 min. Aliquots were separated in a 4% nondenaturing polyacrylamide gel 
for 1.5 hours at 200 V. The gel was dried and subjected to autoradiography. 
 
Generation and concentration of retrovirus 
The Phoenix retrovirus expression system (Orbigen, San Diego, CA Cat. No. RVK-
10001) was used to generate retroviruses for expression of the Runx1 mutant panel per 
manufacturer’s instructions. Phoenix eco cells (a proprietary 293T derivative grown in 
DMEM with 10% FBS) were co-transfected with 5 ug pMIG plasmid and 2.5 ug φeco 
plasmid using Superfect (Qiagen). After 24 and 48 hours the media was replaced. Media 
containing retroviruses was collected and then replaced the 3rd, 4th and 5th days after 
transduction, as we determined those time points provided the most infectious virus. 
Collected virus containing media was spun at 25000 rpm for 3 hours and then 
resuspended in one fifth the original volume to concentrate the virus for better infection.    
 
Transduction of bone marrow cells 
Bone marrow cells were isolated by washing the marrow space of  femurs and tibiae of 8-
12 week old donor mice.  200,000 cells were resuspended in 1 mL of complete media 
(RPMI with 20% FBS, 6 ng/mL IL-3, 10 ng/mL IL-6, and 10 ng/mL SCF). 1 mL of 
concentrated virus was added and cells were spun at 2400 rpm for 90 min at 30ºC. 
Following the spin, cells were incubated at 37ºC for 3 hours before resuspension in fresh 
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complete media. This infection was repeated then next day. 24 hours after the second 
infection cells were taken to the University of Massachusetts flow cytometry core facility 
and sorted for GFP expression.  
 
Colony Forming Unit (CFU) assays 
GFP positive transduced bone marrow cells (10,000 ) were resuspended in Iscove's 
Modified Dulbecco's Medium (IMDM) without serum, and plated in duplicate (2000 
cells per plate) in 35-mm dishes containing Methocult methyl cellulose medium 
(StemCell Technologies Vancouver, BC, Canada Cat. No. M3434) for CFU assay per the 
manufacturer’s instructions. Colonies were counted by visual inspection after 7 days of 
incubation at 37°C. 
 
Microarray and qRT-PCR 
RNA was prepared from 1 million of the stably transduced 32D cells using TRIzol 
following the manufacturer’s protocol (Invitrogen). For microarray analysis, total RNA 
was processed by the University of Massachusetts Genomics Core Facility and run on 
Affymetrix MouseGene 1.0 ST arrays. GeneSpring software (Agilent Technologies) was 
used to determine which genes had expression changes of at least 1.5 fold, and that gene 
list was further analyzed using the Database for Annotation, Visualization and Integrated 
Discovery (DAVID)30 software suite for gene ontology and promoter motif analysis. 
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RNA samples for microarray confirmation were treated with DNaseI and 1 ug was 
subjected to reverse transcription with oligo dT primers. Quantitative PCR was 
performed on the resulting cDNA using the primers in Table 2.  
 
 
Table 2: qRT-PCR primers to confirm microarray data in 32D stable cell lines 
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Results 
Runx1 C-terminal mutations in DNA binding and target activation 
In order to study contributions of precise domains within Runx1, we used site-directed 
mutagenesis to generate a panel of Runx1 mutations (Figure 4). Luciferase assays using 
HeLa cells transfected with the Runx1 C-terminal mutations showed that the truncation 
and subnuclear targeting mutants failed to activate the GM-CSF promoter to the same 
extent as wildtype Runx1 (Figure 5; p=0.012, 0.037 and 0.11 for Runx1Q307X, Runx1Y352A 
and Runx1HTY350-352AAA, respectively). The PPXY domain mutant Runx1Y357A did not 
reduce activation of the GM-CSF promoter (Figure 5). DNA binding ability was retained 
in all of the C-terminal mutations, indicating a different mechanism for the deregulation 
of the GM-CSF promoter (Figure 6). 
 
 
Figure 4: Panel of Runx1 mutations to investigate C-terminal domains 
Site directed mutagenesis was used (Table 1) to generate a panel of Runx1 mutants to model: loss 
of DNA binding (R174Q), C-terminal truncation (Q307X), aberrant subnuclear targeting 
(Y352A), aberrant subnuclear targeting and loss of co-factor interactions (HTY350-352AAA), 
and loss of PPXY motif.  
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Figure 5: Runx1 C-terminal mutants and promoter activation 
HeLa cells were co-transfected with empty vector (EV), wildtype, or mutant Runx1 and a 
luciferase construct driven by the GM-CSF promoter. Plotted is the relative luciferase activity 
using renilla as a background control and normalizing to empty vector (n=3 transfections for each 
construct). *p<0.05, calculated by Student’s T test. 
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Figure 6: DNA binding is retained in Runx1 C-terminal mutants 
(A) IVTT generated wildtype and mutant Runx1 in Electrophoretic Mobility Shift Assay (EMSA) 
using the Runx consensus oligonucleotide 5’-CGA GTA TTG TGG TTA ATA CG-3’. 
The rightmost lanes show Q307X with the addition of cold wildtype (WT) or mutant (Mut) 
competitor oligo. Free probe is visible at the bottom of the gel. (B) Western blot using anti-flag 
antibody with 2 uL of the IVTT generated lysate as in A. 
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Transduction of primary cells with Runx1 C-terminal mutations 
After establishing DNA binding and promoter activation of the Runx1 mutations in HeLa 
cells, we transitioned into hematopoietic cells for further experiments. Hematopoietic 
cells are difficult to transfect, so we used site directed mutagenesis to develop the same 
panel of mutations in a retroviral expression vector that included an IRES-GFP, pMIG.105 
This vector allowed purification of even a very small percentage of transduced cells by 
flow cytometry for GFP expression (Figure 7).  
 
Primary bone marrow cells were transduced with the panel of Runx1 mutants and GFP+ 
cells were sorted for colony forming unit (CFU) assays (Figure 8). Runx1 is known to 
have a growth suppressive role in hematopoietic progenitors61,62,109 and overexpression of 
full length Runx1 suppressed CFU ability of bone marrow cells. Overexpression of 
empty vector, the DNA-binding mutant (R174Q)  or C-terminal truncation (Q307X) had 
significantly more CFU, suggesting that loss of DNA binding or the C-terminus both 
result in a non-functional protein. Interestingly, overexpression of the Runx1 C-terminal 
point mutations had similar CFU to wildtype, indicating that those precise domains are 
not required for growth suppression. 
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Figure 7: Retroviral constructs allow purification of low yield transduction 
(A) The retroviral vector pMIG was used to create a panel of mutants for transduction of 
hematopoietic cells. Runx1 was cloned between bolded NotI and PmeI restriction sites, and 
mutations were made from the wildtype plasmid via site directed mutagenesis (Table 1). (B) 
With the IRES GFP, very low transduction yields could be purified by flow cytometry. Shown is 
a representative sort of empty vector infected cells. 
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Figure 8: Bone marrow CFU assays with Runx1 C-terminal mutants 
Bone marrow cells were retro-virally transduced with empty vector, Runx1 wildtype, Runx1R174Q, 
Runx1Q307X, Runx1Y352A, Runx1HTY350-352AAA or Runx1Y357A, sorted for GFP expression and then 
GFP+ cells (2,000 per plate) were plated in colony forming unit (CFU) assays. The DNA binding 
mutation and C-terminal truncation had similar colonies to empty vector. Wildtype Runx1 , 
Runx1Y352A, Runx1HTY350-352AAA and Runx1Y357A all significantly inhibited colony formation 
(p<0.05, n=6 to 10). Error bars are SEM. 
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Stable cell lines with Runx1 subnuclear targeting mutant 
Our lab previously developed stable cell lines transduced with empty vector, wildtype 
Runx1 and a subnuclear targeting defective mutant (mSTD) Runx1 in 32D cells.87 The 
mSTD mutation is in the human Runx1 cDNA with a point mutation causing Y380A, 
equivalent to Y352A mutant in the mouse transcript (Figure 4). 32D murine myeloid 
progenitor cells are IL-3 dependent, and can be forced to differentiate by replacement of 
IL-3 with GM-CSF in the growth media. We performed CFU assays with these stable 
cells lines under normal growth and differentiation conditions (Figure 9). Under normal 
growth conditions, overexpression of both wildtype Runx1 and mSTD Runx1 suppressed 
colony formation, similar to the results observed in bone marrow cells. After 12 days in 
differentiation media, empty vector and Runx1 overexpressing cells had differentiated 
and lost most of their colony forming ability. In contrast, mSTD Runx1 expression 
caused a differentiation block87 and those cells maintained colony forming ability. These 
results highlight the importance of cellular context on Runx1 activity and differences in 
the effect of Runx1 mutations in progenitor cells versus their further differentiated 
progeny. 
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Figure 9: Stable 32D cell line CFU assays 
32D stable cell lines overexpressing empty vector, wildtype Runx1 or subnuclear targeting 
defective mutant Runx1 (mSTD) were plated in CFU assays from growth media, or after 12 days 
in differentiation medium (n=2 each). Error bars are SEM. * p<0.05, ** p<0.01, calculated with 
Student’s T test. 
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Previous characterization of the 32D stable cell lines found deregulation of many myeloid 
genes.87 We examined global gene expression of the 32D stable cell lines under normal 
growth conditions with microarray analysis. Gene expression in wildtype Runx1 
overexpressing cells was compared to mSTD overexpressing cells. Four samples were 
prepared for each cell line. Three were used as replicates in the microarray analysis 
(Table 3) while the fourth was used to confirm altered gene expression by qRT-PCR 
(Figure 10). Functional annotation clustering revealed enrichment of several gene 
ontology terms (Table 4). The terms for deregulated genes correlate with the 
differentiation block observed in these cells, as they are involved with immune response 
or important functions of mature monocytes / macrophages. Promoter analysis of genes 
deregulated in the progenitor cells harboring subnuclear targeting defective Runx1 
revealed the predominant DNA binding motifs were not the canonical Runx motif, but 
motifs of known Runx1 co-factors PU.1, CEBPβ, CEBPα, and ETS1 (Figure 11). 
Enrichment of co-factor binding motifs indicates a non-DNA binding mediated role for 
mSTD Runx1 is driving these expression changes, and support the importance of Runx1 
scaffolding functions during gene regulation. 
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Table 3: Gene list from microarray data 
The mean ratio of expression change shown by microarray analysis was calculated using 32D 
cells stably expressing wildtype versus mSTD Runx1 with GeneSpring software (n=3 of each). 
Listed are transcripts of known genes that reached the threshold of either expression 0.7 fold 
lower or 1.5 fold higher in mSTD expressing cells. 
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Figure 10: qRT-PCR of 32D stable lines confirms microarray data 
Global gene expression of 32D stable cell lines with empty vector (EV), wildtype Runx1 (WT) or 
subnuclear targeting defective mutant Runx1 (mSTD) was analyzed by microarray analysis 
(n=3). Altered expression levels of several genes was confirmed by qRT-PCR using an 
independent sample of each cell line. Relative expression levels shown are normalized to mCox. 
Mean relative expression is plotted, with error bars showing the range between 2 technical 
replicates. 
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Table 4: Gene Ontology from 32D stable cell microarrays 
Gene Ontology terms for the most highly enriched gene clusters comparing stably overexpressing 
wildtype Runx1 versus mSTD Runx1 (n=3). Genes with a mean difference in expression of at 
least 1.5 fold were used in the analysis. Shown are the term for a cluster, the calculated Fisher 
exact p value, and the gene symbols within that cluster. Clustering performed with DAVID 
bioinformatics resources.30 
 
 
Figure 11: Motif analysis of deregulated genes in 32D stable cell lines 
DAVID motif analysis of the deregulated genes in 32D cells overexpressing mSTD Runx1. The 
enriched motif, transcription factor predicted to bind that motif and p value for the enrichment are 
shown. P values calculated using Benjamini-Hochberg correction for false discovery rate. 
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Discussion 
Runx1 is a frequent target for mutation and translocation in hematopoietic 
disease.77,78,92,93,95,102 The mutations that retain DNA-binding ability lose C-terminal 
domains88,96 critical for co-factor interactions and subnuclear targeting.19-21,25,103 Loss of 
Runx1 C-terminal domains represents a potential common leukemic mechanism. 
Therefore, we developed a panel of Runx1 C-terminal mutations to examine the roles of 
these lost domains in vitro. 
 
Runx factors can suppress cell growth and proliferation.27,109-113 Within hematopoiesis, 
this function of Runx1 is highly context dependent114,115, and so are the consequences of 
mutations within C-terminal domains. Overexpressed in primary cells, or in a stable cell 
line, subnuclear targeting defective mutants behave in the same way as wildtype Runx1 
in colony forming assays. However, if the cells are pushed toward differentiation the 
difference between wildtype and mSTD Runx1 are dramatic. Even with the same assay 
and in the same cells, the effects of altering Runx1 subnuclear targeting differ in the 
presence of differentiation promoting growth factors. This supports Runx1 relaying 
external signals while organizing regulatory machinery26 and connects subnuclear 
targeting with an additional layer of regulatory control.   
 
While mutations in the C-terminus of Runx1 do not interfere with DNA-binding, they do 
alter promoter activation. Our group has previously reported that stable overexpression of 
33 
 
mSTD Runx1 blocks differentiation.87 Examination of global gene expression in these 
cells before they were given any differentiation signal revealed that deregulation of genes 
important for monocyte/macrophage cell function was already underway. Importantly, 
the genes deregulated by mSTD Runx1 did not require Runx1 binding in their promoters. 
Instead the promoters of deregulated genes were enriched for the binding motifs of 
several known Runx1 co-factors. Known protein-protein interaction domains for the 
enriched co-factors are N-terminal to the NMTS and therefore direct interactions should 
have been maintained.116-118 These data provide strong evidence for Runx1 scaffolding 
co-factors and DNA as part of complex regulatory networks.   
 
The context dependent nature of normal Runx1 function during hematopoiesis and of the 
C-terminal Runx1 mutations supports study of these mutants at endogenous levels in 
vivo. A point mutation disrupting subnuclear targeting has profound effects on a myeloid 
progenitor cell line, but additional consequences in other hematopoietic lineages are 
likely. Runx1 is important during differentiation of many hematopoietic 
lineages64,66,75,80,119 and additional non-hematopoietic roles of Runx1 in the hair 
follicle120-122 or bone development123,124 could also be affected. Taken together, these in 
vitro data on the effects of C-terminal Runx1 mutations support the concept of 
transcription factors scaffolding regulatory machinery within subnuclear domains and 
warrant further investigation at endogenous expression levels in vivo. 
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Chapter 3: Definitive Hematopoiesis Requires Runx1 C-Terminal-
Mediated Subnuclear Targeting and Transactivation 
 
Runx1 is a key hematopoietic transcription factor required for definitive hematopoiesis 
and is a frequent target of leukemia-related chromosomal translocations. The resulting 
fusion proteins, while retaining DNA binding activity, display loss of subnuclear 
targeting and associated transactivation functions encoded by the C-terminus of the 
protein. To define the precise contribution of the Runx1 C-terminus in development and 
leukemia, we created a knock-in mouse with a C-terminal truncation by introducing a 
single nucleic acid substitution in the native Runx1 locus. This mutation (Runx1Q307X) 
models genetic lesions observed in patients with leukemia and myeloproliferative 
disorders. The Runx1Q307X homozygous mouse exhibits embryonic lethality at E12.5 due 
to central nervous system hemorrhage and a complete lack of hematopoietic stem cell 
function. While able to bind DNA, Runx1Q307X is unable to activate target genes, 
resulting in deregulation of various hematopoietic markers. Thus, we demonstrate that the 
subnuclear targeting and transcriptional regulatory activities of the Runx1 C-terminus are 
critical for hematopoietic development. We propose that compromising the C-terminal 
functions of Runx1 is a common disease mechanism for somatic mutations and leukemic 
fusion proteins observed in human patients. 
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Introduction 
Runx1 is required for the emergence10,59 and possibly the maintenance60-62 of 
hematopoietic stem cells (HSCs) and is important throughout definitive 
hematopoiesis.79,125 Runx1 is also frequently mutated in hematological disorders and 
malignancy. Point mutations and translocations of Runx1 are associated with acute 
myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), myeloid 
dysplastic syndromes (MDS), refractory anemia with excess blasts (RAEB) and familial 
platelet disorder (FPD) which also has a predisposition toward AML.77,78,88,92-94 Somatic 
mutations observed in patients cluster either in the N-terminal DNA-binding Runt 
Homology Domain (RHD) or within the C-terminus.96 Runx1 mutations in the C-
terminus of CMML patients have been shown to predict transformation to AML.92 The 
domains disrupted by the C-terminal mutations are critical for many protein-protein 
interactions18-21 and for appropriate subnuclear targeting of Runx1.25,49,51,87 Consequently, 
cells harboring these mutations exhibit deregulation of Runx1 target genes.87 Loss of C-
terminal residues critical for subnuclear targeting enhances proliferation of myeloid 
progenitor cells concomitant with a differentiation block, affecting a transformed 
phenotype.87,103 This is reminiscent of the effects of various chromosomal translocations 
that retain the RHD of Runx1 but replace the C-terminus with segments of other proteins, 
generating leukemic fusion proteins such as Runx1/ETO, Runx1/Evi1 and Runx1/MDS. 
The chimeric fusion proteins retain DNA binding ability, but lose co-factor interactions 
important for gene regulation. These results strongly suggest a role of the Runx1 C-
terminus and associated functions in the biology of hematopoiesis and leukemogenesis. 
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To directly examine the biological relevance of the Runx1 C-terminus in vivo, we 
introduced a premature translational stop codon after amino acid 307, mimicking Runx1 
mutations identified in human MDS/AML and CMML patients (Figure 12) and observed 
to cause MDS/AML in mouse bone marrow transfer models.92,96,126,127 The truncated 
Runx1, Runx1Q307X, lacks the transactivation domain and nuclear matrix targeting signal 
(NMTS) but retains sequences for the entire endogenous Runx1 mRNA, in contrast to a 
previous mouse model that replaced a portion of the mRNA with bacterial LacZ 
sequences.58 Retaining the full endogenous mRNA avoided interfering with any small 
RNA mediated regulation. In this study, Runx1Q307X homozygous mice die at embryonic 
day 12.5 (E12.5) from central nervous system hemorrhages and a lack of HSC function. 
These results phenocopy the complete DNA binding knockout.10 We also show 
deregulation of genes important for hematopoiesis and HSC function in E12.5 
Runx1Q307X homozygous embryos. Our results demonstrate that the transactivation and 
subnuclear targeting domains lost in Runx1Q307X are essential for Runx1 function during 
development. 
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Figure 12: Runx1 patient mutations and mouse models.   
Diagram of Runx1 with regions of interest highlighted. Runx1Q307X was designed to model 
several human mutations observed in MDS, AML, RAEB and CMML. Also illustrated are the 
first RHD knock out mouse, existing mouse models bearing patient mutations in the RHD and 
previous models with mutations in the Runx1 C-terminus.  Runx1-LacZ is broken to illustrate the 
full length of the chimeric fusion protein.   
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Materials and Methods 
Immunofluorescence microscopy  
HeLa cervical carcinoma cells were grown on cover slips coated with 0.05% gelatin and 
transfected with Fugene 6 (Roche Diagnostics, Indianapolis, IN) following 
manufacturer’s instructions. After 24 hours cells were fixed using formaldehyde (3.7%), 
and permeabilized with 0.5% Triton X-100 for whole-cell preparations. Nuclear matrix-
intermediate filament preparations were obtained as described.36 Soluble proteins were 
extracted with cytoskeletal buffer (CSK; 10 mM Pipes, pH 6.8/300 mM sucrose/100 mM 
NaCl/3 mM MgCl2/1 mM EGTA/20 mM vanadyl riboside complex/1 mM 4-(2-
aminoethyl)benzenesulfonyl fluoride) containing 0.5% Triton X-100 for 5 min on ice. 
After washing in CSK, DNA and associated proteins were removed by digestion with 400 
units/mL DNase I for 50 min at 30°C in digestion buffer (10 mM Pipes, pH 6.8/300 mM 
sucrose/50 mM NaCl/3 mM MgCl2/1 mM EGTA/20 mM vanadyl riboside complex/1 
mM 4-(2-aminoethyl)benzenesulfonyl fluoride). A final wash with 0.25 M ammonium 
sulfate extraction buffer (10 mM Pipes, pH 6.8/250 mM ammonium sulfate/300 mM 
sucrose/3 mM MgCl2/1 mM EGTA/20 mM vanadyl riboside complex, 1 mM 4-(2-
aminoethyl)benzenesulfonyl fluoride) removed remaining cut DNA. Digestion was 
confirmed by DAPI staining.  Runx1 protein was detected by the AML1(RHD) antibody 
(Oncogene Science, Cambridge, MA; 1:200 dilution) followed by fluorochrome-
conjugated Alexa Fluor 488 secondary antibody (Invitrogen Molecular Probes, Eugene, 
OR; 1:800 dilution). Cells were mounted in Prolong Gold antifade mounting medium 
(Invitrogen Molecular Probes). Fluorescence and transmitted light images were captured 
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using a Zeiss Axioplan 2 microscope equipped with a digital charged-coupled device 
camera (Hamamatsu Photonics, Bridgewater, NJ Cat. No. C4742-95) interfaced with the 
MetaMorph Imaging System (Universal Imaging Corporation Ltd, Marlow, 
Buckinghamshire, UK). 
 
Luciferase assays 
K562 erythroleukemia or HeLa cells were transfected with Fugene 6 (Roche) following 
manufacturer’s instructions. For both cell types, each well (200,000 cells) of a 6-well 
plate was transfected with 500 ng of GM-CSF promoter luciferase reporter (pGL3)103; 
200 ng of pcDNA3.1/HISa (Invitrogen) empty vector, Runx1 wild type or Runx1Q307X; 
and 5 ng pHRL-null promoter-less Renilla luciferase.106 Luciferase activity was measured 
24 hours after transfection using the Dual-Luciferase Reporter Assay System (Promega, 
Madison, WI Cat. No. E1960) in a Glomax Luminometer (Promega) with Glomax 1.6 
software. Values plotted are the ratios of firefly to Renilla luciferase, normalized to 
empty vector.  
 
Electrophoretic Mobility Shift Assay (EMSA) 
Runx consensus oligonucleotide 5’-CGA GTA TTG TGG TTA ATA CG-3’ was end 
labeled as described previously.107,108 Upper strands of the oligonucleotides were labeled 
with 32P for 1 hour at 37°C in a 50 uL volume using T4 Polynucleotide Kinase (New 
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England BioLabs, Beverly, MA) following manufacturer’s instructions. The reaction was 
stopped by heat inactivation at 65°C for 1 hour. Annealing was performed by addition of 
a twofold excess amount of bottom strand followed by boiling for 5 min and slow cooling 
to room temperature. Unincorporated nucleotides were removed with a quick-spin G 25 
Sephadex column (Roche Molecular Biochemicals, Indianapolis, IN) according to the 
manufacturer's instructions. Nuclear extracts from HeLa cells (7.5 ug) transduced with 
empty vector, wildtype Runx1 or Runx1Q307X were used in the binding reaction. Reaction 
mixtures were prepared using 50 fmol of probe, 50 mM KCl, 1 mM magnesium chloride, 
1 mM DTT, 2 mM sodium fluoride, 2 mM sodium vanadate, 10% glycerol, 2 µg of 
poly(dI-dC)•poly(dI-dC), and DNA binding reactions were carried out at 25˚C for 20 
min. Aliquots were separated in a 4% nondenaturing polyacrylamide gel for 1.5 hours at 
200 V. The gel was dried and subjected to autoradiography. 
 
Construction of the Runx1
Q307X 
expression vector 
Wild type Runx1 in the pcDNA3.1/HISa expression vector104 was mutated to Runx1Q307X 
by site directed mutagenesis using a QuikChange Site-Directed Mutagenesis Kit 
(Stratagene, La Jolla, CA) with the following primers: forward CGG CGA CCC ACG 
CTA GTT CCC TAC TCT G, reverse CAG AGT AGG GAA CTA GCG TGG GTC 
GCC G. 
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Construction of the Runx1
Q307X
 targeting vector  
We targeted the mouse Runx1 locus by homologous recombination using a 3.97 kb SacII-
NotI PCR fragment of intron 7 (left arm) and a 4.0 kb NotI-SalI PCR fragment of intron 7 
- exon 8 (right arm). Both fragments were generated from mouse AB2.2 genomic DNA 
by PCR using specific primer pairs (Primers 5’ to 3’: LAF1 CCG CGG GGC ATC TCT 
CTC CTT CCT CCA GTG TCT ; LAR1 GAG GGG ATC GAA AAG CTT CCT ; LAF2 
AGG AAG CTT TTC GAT CCC CTC; LAR2 GCG GCC GCG ATC ACG GAG AGT 
GCC TCT GAC AC; RAF1 GCG GCC GCG TGG GCA GGA GCA CTC GCT GT; 
RAR1 GAG TAG GGA ACT AGC GTG GG; RAF2 CCC ACG CTA GTT CCC TAC 
TC; RAR2 GAC CAC CCA GAT GCA AAC AGG; RAF3 CGC ACC TTA TCG ATT 
GCA A; RAR3 GTC GAC CCG ACC AAC AGC CAA ACC CAC CAA). The left arm 
was created by using two primer pairs that produce 1.3 kb and 2.67 kb fragments (LAF1 
to LAR1 and LAF2 to LAR2, respectively) which were ligated using an internal HindIII 
site to obtain the entire 3.97 kb fragment. The right arm was created using three different 
primer pairs that produce two overlapping fragments of 1.0 kb containing the stop codon 
mutation (RAF1 to RAR1 and RAF2 to RAR2) and 3.0 kb (RAF3 to RAR3) which were 
ligated using an internal ClaI site to obtain the entire 4.0 kb fragment. The 3.97 kb and 
4.0kb fragments were cloned in tandem into the pGEM-5Zf(+) vector (Promega). We 
then inserted a 2.0 kb NotI-NotI cassette containing a floxed neomycin gene (LoxP site - 
PGK promoter - Neo cDNA - LoxP site) and a 2.2 kb SalI-SalI cassette with the 
thymidine kinase gene (PGK promoter - TK cDNA). Vectors containing the Neo and TK 
cassettes were provided by the Transgenic Animal Modeling Core Facility of the 
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University of Massachusetts Medical School. The final targeting vector and intermediate 
constructs were subjected to DNA sequencing. 
 
Screening of mouse embryonic stem cells with a Runx1
Q307X
 allele 
 The targeting vector was linearized with AscI digestion and electroporated into PC3 
(129S5/SvEvBrd) embryonic stem (ES) cells (Transgenic Animal Modeling Core 
Facility, University of Massachusetts Medical School) (i.e., 107 ES cells were transfected 
with 20 ug linearized construct at 230 V and 500 uF). Positive selection was started 24 
hours after electroporation by addition of 180 ug/mL of G418 (Invitrogen Life 
Technologies, Inc., Carlsbad, CA). Thymadine kinase was used to select against non-
homologous recombination events. Resistant clones were transferred into and cultured in 
96-well plates. Homologous recombination of the Runx1Q307X allele was established by 
Southern blot analysis using restriction sites and probes external to the targeting vector. 
Hybridization was carried out using the PerfectHybtm Plus Hybridization kit (Sigma-
Aldrich, St. Louis, MO). Southern blot analysis identified a single clone with a correctly 
targeted mutation of the Runx1 locus. 
 
Generation of the Runx1
Q307X
 mice 
The PC3 ES cell clone with a targeted Runx1Q307X allele was micro-injected into 
C57BL/6 blastocysts. Chimeric mice with a significant ES cell contribution (as 
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determined by agouti coat color) were mated with wild type C57BL/6 and germ line 
transmission of the mutant allele was determined by Southern blot genotyping of tail 
DNA from offspring and confirmed by PCR (Primers 5’ to 3’: forward ACT CTG GCA 
GTC TAG GAA GCC, reverse AGG CGC CGT AGT ATA GAT GGT A). Runx1Q307X 
heterozygous mice were crossed to generate Runx1Q307X homozygous mice and offspring 
were subjected to genotyping by PCR and Southern blot analysis. 
 
Histology 
Embryos (E12.5) were embedded in paraffin after a sample of tail was taken for 
genotyping. Six micron sections were stained with hematoxylin and eosin by standard 
procedures. Images were captured using a Axioskop 40 (Carl Zeiss, Inc., Maple Grove, 
MN) equipped with a AxioCam HRc and AxioVision Rel. 4.7 software (Zeiss). 
 
Western blotting 
Embryos (E12.5) were homogenized with a Dounce homogenizer in 2.0 mL direct lysis 
buffer (2% SDS, 2 M urea, 10% glycerol, 10 mM Tris-HCl [pH 6.8], 0.002% 
bromophenol blue, 10 mM DTT, 1× Complete protease inhibitor [Roche], 25 uM MG132 
and 1 mM PMSF). HeLa cells were lysed with 500 uL direct lysis buffer per confluent 
well of a 6-well plate. Cell lysates were boiled for 5 min and equal amounts of protein 
(embryos) or sample volumes (HeLa cells) were electrophoresed in an 8% SDS-
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polyacrylamide gel, at 100V for 1.5 hours. Separated proteins were transferred to an 
Immobilon Membrane (Millipore, Billerica, MA) by semidry transfer for 30 - 45 min at 
10V. Membranes were blocked for at least 1 hour in 5% nonfat dry milk in PBST (PBS 
with 0.1% Tween 20) and then probed for 1 hour with  primary antibody diluted 1:1000  
(PU.1, YAP, Cdk2, LaminB [Santa Cruz Biotechnology, Santa Cruz, CA] or 
AML1(RHD) [Oncogene Science]). After four 5 min washes with PBST, blots were 
incubated for 1 hour with goat anti-rabbit (or donkey anti-goat) IgG-HRP secondary 
antibody diluted 1:4000, washed four times for 5 min in PBST and detected with ECL 
(Perkin-Elmer, Waltham, MA). 
 
Colony Forming Unit (CFU) assays 
Fetal livers of E12.5 embryos were isolated, placed in Iscove's Modified Dulbecco's 
Medium and passed three times through a 26 gauge needle to homogenize the mixture. 
Cells (20,000) from each liver were plated in duplicate in 35-mm dishes containing 
Methoculttm methyl cellulose medium (StemCell Technologies Vancouver, BC, Canada 
Cat. No. M3434), incubated at 37°C and colonies were counted by visual inspection on 
day 7. 
 
qRT-PCR 
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RNA was prepared from E12.5 embryos using TRIzol following the manufacturer’s 
protocol (Invitrogen). RNA was treated with DNaseI and 1 ug was subjected to reverse 
transcription with oligo dT primers. Quantitative PCR was performed on the resulting 
cDNA using the primers in Table 5. 
 
Table 5: qRT-PCR primers used in Runx1
Q307X
 embryos 
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Results 
Loss of Runx1 C-terminal domains causes aberrant subnuclear targeting 
The region lost in Runx1Q307X includes the NMTS, a domain required for subnuclear 
targeting of Runx1 to transcriptionally active sites. In contrast, previous mouse models 
have focused on the Runt-homology DNA binding domain or substituted the C-terminus 
with LacZ to track expression (Figure 12). To examine subnuclear targeting of the 
mutated protein, nuclear matrix-intermediate filament (NMIF) preparations of HeLa cells 
transduced with wild type Runx1 or Runx1Q307X were examined by in situ 
immunofluorescence microscopy. Expression of the truncated Runx1Q307X (denoted ΔC in 
figures) was confirmed by Western blot (Figure 13A). In whole cell preparations, 
Runx1Q307X retained the characteristic punctate nuclear foci observed with wild type 
Runx1 (Figure 13B). However, the Runx1Q307X signal was significantly reduced in NMIF 
preparations, indicating that this mutant has lost the ability to interact with the nuclear 
matrix (Figure 13B). Thus, our results are consistent with previous observations that the 
C-terminally encoded NMTS of Runx1 is required for subnuclear targeting.87,103 We 
performed luciferase reporter assays to determine if Runx1Q307X is able to activate target 
promoters. The GM-CSF promoter was activated in the presence of wild type Runx1, but 
Runx1Q307X activated the promoter to similar levels at the empty vector control, in both 
HeLa and K562 cells (Figure 13C). Runx1Q307X forms stable protein-DNA complexes in 
electrophoretic mobility shift assay (EMSA) (Figure 13D). Thus, while Runx1Q307X is 
capable of binding to DNA, this truncated protein is unable to associate with the nuclear 
matrix and failed to fully activate target gene promoters.   
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Runx1 translocations observed in human leukemia patients often lose C-terminal domains 
critical for subnuclear targeting and protein-protein interactions. Previous mouse models 
examined complete loss-of-function Runx1 mutations by ablating DNA binding. Other 
mutants created hypomorphic deletions or fusion proteins produced from chimeric 
mRNAs lacking endogenous 3’UTR sequences that are required for fidelity of 
expression. We investigated the biological function of the Runx1 C-terminus by 
introducing the Runx1Q307X point mutation into the endogenous Runx1 locus by 
homologous recombination (Figure 14). Southern blot analysis identified ES clones with 
correctly targeted mutation of the Runx1 locus, from which the mice were generated 
(Figure 15). 
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Figure 13: Characterization of Runx1
Q307X
 in vitro 
(A) Western blot showing expression of wildtype Runx1 or Runx1Q307X in transfected HeLa cells, 
with Cdk2 shown as a loading control. (B) Whole cell (upper panels) or NMIF preparations 
(lower panels) of HeLa cells transfected with wildtype Runx1 or Runx1Q307X. Anti-Runx1 
immunofluorescence images are shown with phase contrast insets.  Scale bars are 100 um. The 
signal for Runx1Q307X cells in NMIF preparations decreased by 4.5 fold compared to wild type 
Runx1, based on observation of at least 200 cells per sample with representative cells shown. (C) 
Luciferase expression from GM-CSF promoter constructs in the presence of empty vector, 
wildtype or Runx1Q307X in HeLa and K562 cells. Luciferase activity is normalized to background 
Renilla and error bars represent the standard deviation between multiple samples (n=3 HeLa, 4 
K562). (D) EMSA showing DNA binding activity of wildtype Runx1 and Runx1Q307X from 
transduced HeLa cell nuclear extracts: lane 1, free probe; lane 2, empty vector; lane 3, wildtype 
Runx1; lane 4, Runx1Q307X.  
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Figure 14: Targeting vector for Runx1
Q307X
 mice  
Targeting strategy to replace a portion of Exon 8 with Exon 8 containing the point mutation to 
cause a stop codon after amino acid 307 (CAG to TAG). Probes A and B and restriction enzyme 
cut sites are shown. The Neomycin resistance gene (Neo) was removed by using embryonic stem 
cells containing the sperm-specific PC3Cre, excising Neo during generation of founder mice. 
Southern blot analysis of genomic DNA from tails of E12.5 embryos was performed using 
restriction enzymes and probes shown.     
 
 
Figure 15: Genotyping of Runx1
Q307X
 mice. 
Genotyping by Southern blot, with the ES cells containing the Neo cassette shown as an 
additional control confirming Neo excision. 
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Runx1 C-terminal subnuclear targeting and associated transactivation are required 
during development 
Embryos homozygous for the truncated Runx1Q307X died at E12.5 from central nervous 
system hemorrhage, similar to the Runx1 RHD mutant knockout mice.10 We observed 
near Mendelian ratios of wild type, heterozygous and homozygous mutant pups at E11.5 
and E12.5 (Table 6). However, no live homozygous Runx1Q307X pups were observed at 
E13.5 (Table 6). Gross examination of homozygous embryos consistently showed 
multiple areas of hemorrhage and a pale fetal liver (Figure 16A). The severity of the 
phenotype ranged from a few small areas of hemorrhage in the spinal cord to large 
regions of hemorrhage throughout the spinal cord, isthmus and ventral metencephalon 
(Figure 17). Areas of hemorrhage were examined in more detail with whole mount 
hematoxylin and eosin staining (Figure 16B and C). The sinusoids of Runx1Q307X 
homozygous embryo fetal livers were devoid of hematopoietic precursor cells that were 
present in wild type embryos (Figure 16C middle and lower panels). 
 
Table 6: Genotyping of embryos from Runx1
Q307X
 heterozygous intercrosses.   
Genotyping was performed by Southern blot as shown in Figure 14 or by PCR using the 
following primers, Forward primer ACT CTG GCA GTC TAG GAA GCC and Reverse 
primer AGG CGC CGT AGT ATA GAT GGT A. *At E13.5 only live embryos were 
counted. 
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Figure 16:  Histology of Runx1
Q307X
 homozygous embryos at E12.5.   
(A) Gross image of wild type (left panel) and Runx1Q307X (right panel) E12.5 embryos.  
White arrowheads note sites of hemorrhage in the Runx1Q307X embryo. Scale bars are 1 
mm. (B) Whole mount hematoxylin and eosin staining of embryos in A. Scale bars are 1 
mm. (C) Magnification of heads of E12.5, noting hemorrhages with black arrows (upper 
panels, scale bars are 500 um). Magnification of fetal livers of E12.5 embryos (middle 
panels, scale bars are 250 um) and magnification showing liver sinusoids (lower panels, 
scale bars are 100 um) with arrow noting the hematopoietic precursor cells in the wild 
type sinusoids that are absent from Runx1Q307X.       
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Figure 17: Variation in phenotype of Runx1
Q307X
 homozygous embryos. 
E11.5 (top row) and E12.5 Runx1Q307X homozygous embryos display a range of 
hemorrhage severity. Heterozygous (+/ΔC) and wildtype (+/+) E12.5 embryos are shown 
for comparison. Scale bars are 1mm. 
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Consistent with the absence of hematopoietic progenitor cells by histological analysis, 
fetal liver cells from Runx1Q307X homozygous embryos were unable to form colonies in a 
methocellulose colony forming unit assay (Figure 18A) despite robust activity of fetal 
liver cells from their wild type and heterozygous littermates. Runx1 is not required for 
embryonic primary erythropoiesis and primitive erythrocytes are abundant in the 
peripheral blood of both wild type and mutant embryos (Figure 18B). Thus, the C-
terminal domains of Runx1 are required for in vivo HSC function during development. 
 
 
Figure 18: Lack of hematopoietic progenitor cell function in Runx1
Q307X
.   
(A) Colony Forming Unit (CFU) assays using fetal liver cells from wild type, 
heterozygous or Runx1Q307X homozygous E12.5 embryos (n=3 to 6). (B) Nucleated 
erythroid progenitors are morphologically normal in peripheral blood smears of wild type 
and Runx1Q307X E12.5 embryos.  Scale bars are 10 um. 
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Aberrant subnuclear targeting and lost co-factor interactions of Runx1
Q307X
 cause 
deregulation of Runx1 targets 
Runx1 is a key regulator of hematopoiesis and controls many hematopoietic target 
genes.66,79,84,85 Considering the severity of the phenotype of the Runx1Q307X homozygous 
mice, we performed qRT-PCR analysis to measure the effects of Runx1Q307X on Runx1 
target genes and markers of hematopoiesis (Figure 19). Expression of hematopoietic 
transcription factors (Figure 19A) and phenotypic markers (Figure 19B) was decreased in 
the Runx1Q307X homozygous mice, with a gene dosage dependent reduction generally 
seen in heterozygous littermates. Runx1 expression was not substantially altered, 
suggesting that the point mutation does not change the stability of the transcript (e.g., 
nonsense mediated mRNA decay). Markers for cell survival and proliferation were 
comparable for the three genotypes (Figure 19C). Genes important for HSC function 
(Figure 19D) were dramatically down regulated in the Runx1Q307X homozygous mice, 
confirming the hematopoietic specificity of the mutation. Signaling proteins that are 
indirect targets were also affected in Runx1Q307X mice (Figure 19E). Interestingly, VEGF 
was upregulated in the Runx1Q307X homozygous mice, which may contribute to the 
observed hemorrhages by increasing vascular permeability. Consistent with mRNA 
expression data, a drop in protein levels of PU.1 and YAP was observed (Figure 20). 
These results indicate that the loss of key domains responsible for protein-protein 
interactions with co-factors and subnuclear targeting in Runx1Q307X cause widespread 
gene deregulation.  
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Figure 19: Runx1
Q307X 
causes deregulation of hematopoietic genes.  
Relative expression of hematopoietic transcription factors (A), phenotypic markers (B), 
proliferation and cell survival markers (C), genes required for HSC maintenance (D), and 
signaling molecules (E) by qRT-PCR in wildtype, heterozygous and homozygous 
Runx1Q307X E12.5 mice (N= 3, 2, and 4, respectively). Each point represents the mean of 
technical replicates from one embryo. Results were normalized to mCox expression. See 
Table 5 for specific primers.   
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Figure 20: Western blots confirm altered expression. 
Altered protein levels were confirmed between wildtype, heterozygous and homozygous 
Runx1Q307X E12.5 embryos by Western blot for two genes with decreased mRNA. 
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Discussion 
Human leukemias often involve Runx1 translocations that result in a fusion protein 
retaining the DNA binding domain of Runx1 but losing the C-terminus encompassing 
subnuclear targeting and transactivation domains. By modeling a loss of function 
common in many leukemic fusion proteins we sought to shed light on potential common 
leukemic mechanisms. In this study, we generated a knock-in mouse model that contains 
a point mutation causing a premature stop codon within exon 8. This mutation truncates 
the protein after amino acid 307 but maintains the integrity of the endogenous Runx1 
mRNA by retaining the extensive 3’ untranslated region (UTR) and potential regulation 
by miRNA.75,128 In many human leukemias, a naturally occurring truncated protein 
isoform, AML1a (Runx1/p27129), is up regulated, and there is evidence that over 
expression of AML1a can act as an initiating leukemogenic mutation by inhibiting Runx1 
function.81,130 Taken together, these findings suggest that Runx1 C-terminal domains play 
important mechanistic roles in leukemogenesis and that loss of subnuclear targeting and 
transactivation may contribute to the etiology of human leukemia. 
 
Our mouse model with a point mutation in exon 8 complements previous mouse models 
with mutations in exon 4, which encodes a part of the Runt-homology DNA binding 
domain. These exon 4 mouse mutations mimic genetic lesions found in leukemia 
patients97 and have defined the phenotypic consequences of complete loss of function due 
to impaired DNA binding. Recent evidence has shown the importance of the Runx1 C-
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terminus, which includes subnuclear targeting and transactivation domains, during 
embryoid body formation with mouse ES cells.131 Hematopoietic differentiation was lost 
in embryoid bodies made with Runx1 null ES cells, but rescued by targeted insertion of 
cDNA for full length Runx1 or Runx1 C-terminal truncations that retained transactivation 
domains. Recent in vitro studies used a retroviral rescue of Runx1 null cells to assess 
which domains of Runx1 were important for hematopoietic colony formation.132 These 
studies revealed that the C-terminal transactivation domain is required for colony 
formation, but did not further characterize the rescued cells or address the effects of 
mutation in vivo.  
 
The Runx1Q307X mutation we have characterized here provides a mouse model for Runx1 
C-terminal mutations observed in human patients with MDS, AML, RAEB and 
CMML.92,96 A previous mouse model involving the loss of the Runx1 C-terminus 
replaced exons 7 and 8 with the bacterial LacZ gene to create a fusion protein.58 This 
model allowed the tracking of Runx1 expression and supported the concept that Runx1 is 
required during hematopoietic development. This model also made visualizations of 
Runx1 expressing cells possible throughout development, pinpointing stages where 
Runx1 may play important roles. However, the genetic strategy produced a larger Runx1 
C-terminal deletion than Runx1Q307X and generated a large Runx1-LacZ fusion protein. 
During that process the sequences of the 3’ UTR were necessarily eliminated. It is now 
known that the 3’ UTR of mRNA can be functionally important, as they support 
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regulation by miRNAs (e.g., miR-27a).75 The truncated Runx1Q307X is caused by a single 
point mutation and retains the endogenous 3’UTR. Therefore, any miRNA mediated 
regulation of Runx1Q307X should be identical to endogenous. Runx1, Runx2 and Runx3 
all have homologous subnuclear targeting signals.25,75,133 The Runx1Q307X mouse contains 
a precise mutation that removes only the subnuclear targeting and transactivation 
domains, thus compromising the function of Runx1 as a scaffolding protein attached to 
the nuclear matrix, DNA and other proteins within the complicated three dimensional 
architecture of the nucleus.21,29 The resulting aberrant subnuclear localization of 
Runx1Q307X is predicted to trigger a cascade of deregulation. Taking that into account, it 
is not surprising that this germline mutation has such dramatic consequences for 
definitive hematopoiesis in the developing embryo. 
 
In this study, we show that Runx1Q307X is no longer associated with the nuclear matrix 
due to the loss of domains critical for interaction with the nuclear architecture.  The 
region lost in Runx1Q307X corresponds with the mapped interaction domains for many 
Runx co-factors, including p300, YAP, MOZ, Groucho/TLE1, SUV39H1, Smad3, 
HDAC1 and HDAC3.19-21,23,134-140 Runx1Q307X binds DNA but without the transactivation 
domains or subnuclear targeting it likely obstructs regulation, in a dominant negative 
fashion, rather than bringing components together. Removal of the C-terminal domains of 
Runx1 responsible for subnuclear targeting and protein-protein interactions causes the 
same embryonic lethal phenotype as a DNA binding knockout. Homozygous Runx1Q307X 
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embryos die at E12.5 from lack of definitive hematopoiesis and central nervous system 
hemorrhages. Hence, Runx1Q307X is not a hypomorphic mutation but rather results in a 
phenocopy of RHD mutations. These findings complement the observations with an 
analogous truncation in the Runx2 gene, which was also a phenocopy of a null 
mutation.141 Runx1Q307X contrasts with a mouse mutant lacking the C-terminal VWRPY 
motif, which has a mild hypomorphic phenotype with defects in thymocyte development, 
with other hematopoietic lineages being spared.69 Our results with the Runx1Q307X mouse 
establish that the subnuclear targeting and transactivation functions of Runx1 are 
essential for hematopoietic development and are consistent with the observation that 
human genetic lesions perturbing these functions compromise Runx1 function to 
contribute to leukemogenesis.  
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Chapter 4: A Germline Point Mutation in Runx1 Uncouples its Role in 
Definitive Hematopoiesis from Differentiation 
 
Definitive hematopoiesis requires the master hematopoietic transcription factor Runx1, 
which is a frequent target of leukemia-related mutations and chromosomal translocations. 
Several of the resulting fusion proteins generated by these translocations retain the DNA 
binding activity of Runx1, but lose subnuclear targeting and associated transactivation 
potential. Complete loss of these functions in vivo resembles Runx1 ablation, which 
causes embryonic lethality. We generated a knock-in mouse that expresses full length 
Runx1 mutated in the subnuclear targeting / co-factor interaction domain, Runx1HTY350-
352AAA. Mutant mice survived to adulthood, and hematopoietic stem cell emergence was 
unaltered. However, defects were observed in multiple differentiated hematopoietic 
lineages, precisely at stages where Runx1 is known to play key roles. These findings 
indicate that subnuclear targeting and associated functions of Runx1 are important in 
many compartments throughout hematopoietic differentiation. Thus, a germline mutation 
in Runx1 reveals uncoupling of its roles during embryonic definitive hematopoiesis from 
subsequent differentiation in the adult across multiple hematopoietic lineages. 
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Introduction 
Hematopoietic stem cell (HSC) emergence in the developing embryo requires the key 
Runt-related transcription factor Runx110, which is stringently regulated during 
differentiation of hematopoietic lineages.80,142 Runx1 is one of the most frequent targets 
of point mutations and translocations in human leukemia88, and these mutations cluster in 
either the N-terminal DNA binding domain, or the C-terminal transactivation 
domains.92,96 Many Runx1 mutations cause lethality at embryonic day 12.5 in mouse 
models: defects in DNA binding ability or critical C-terminal functions result in 
phenocopies of the complete null.10,58,143 This lethality has made studying the precise 
roles of Runx1 during hematopoiesis difficult. Genetic restoration of Runx1 expression in 
Tie2-positive endothelial cells rescued HSC emergence but revealed a secondary genetic 
bottleneck of Runx1 deficiency related to perinatal respiratory failure.123 Similar gene 
replacement experiments in which the Runx1 N-terminus was fused to the C-terminus of 
Runx2 or Runx3 rescued HSC emergence, but uncovered additional roles of Runx1 in 
myeloid and T-lymphoid development.144 A conditional null model developed to bypass 
embryonic lethality revealed important roles of Runx1 in most adult hematopoietic 
lineages.66 However, gaps in knowledge remain about the developmental roles of Runx1 
beyond stem cell emergence.  
 
Many transcription factors, including Runx1, localize to specific foci within the nucleus 
and this localization is critical for biological function.18-20,25,49,51,87 Subnuclear targeting 
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defective Runx1 mutants have previously been shown to cause differentiation defects 87 
and altered regulation of target genes, including micro RNA precursors.128 Appropriate 
subnuclear targeting is associated with Runx1 function as a scaffold within the nucleus, 
organizes regulatory machinery and mediates combinatorial control of gene expression.26 
In addition, the leukemic fusion protein Runx1-ETO, which loses Runx1 C-terminal 
domains, exhibits aberrant subnuclear targeting.45,49,51 We previously characterized a 
knock-in mouse with a Runx1 C-terminal truncation that removed domains responsible 
for subnuclear targeting and co-factor interactions.143 This mutation resulted in a 
complete phenocopy of mouse models without Runx1 DNA binding ability and was thus 
not able to address the precise biological contributions of specific domains linked to co-
factor interactions and subnuclear targeting of Runx1.  
 
We have previously characterized the Runx1 NMTS in vitro utilizing several point 
mutations. Those studies showed which residues were the most critical for retention 
within the nuclear matrix fraction of biochemical fractionations, and for appropriate 
activation of a M-CSF promoter driven luciferase reporter construct.103 Those data also 
showed that while a C-terminal truncation could not completely abolish matrix fraction 
retention, a point mutation of one or three amino acids near the end of the NMTS could 
alter fractionation almost as dramatically as the truncation. We developed and 
characterized stable 32D cell lines expressing that single point mutant87 and sought to use 
the triple point mutant, which had a stronger phenotype during the initial in vitro 
characterization, for in vivo studies. 
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In this study, we developed a knock-in mouse model, Runx1HTY350-352AAA, encoding a 
triple point mutation in the C-terminal domain required for subnuclear targeting103 and 
interaction with biologically important co-factors, including SMAD proteins.18-20,134,135,145 
Mice homozygous for Runx1HTY350-352AAA bypass embryonic lethality. However, this 
point mutation influences multiple downstream hematopoietic compartments in which 
there are key roles for wildtype Runx1. Our study establishes that the capability of Runx1 
for interaction with regulatory co-factors and the nuclear architecture is required for 
optimal multi-lineage hematopoietic differentiation. This finding demonstrates that the 
biological role of Runx1 during embryonic development can be uncoupled from its roles 
in differentiation of hematopoietic lineages in the adult. 
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Materials and Methods 
Construction of the Runx1
HTY350-352AAA
 targeting vector  
We targeted the mouse Runx1 locus by homologous recombination using a 3.97 kb SacII-
NotI PCR fragment of intron 7 (left arm) and a 4.0 kb NotI-SalI PCR fragment of intron 7 
- exon 8 (right arm). Both fragments were generated from mouse AB2.2 genomic DNA 
by PCR using specific primer pairs (Primers 5’ to 3’: LAF1 CCG CGG GGC ATC TCT 
CTC CTT CCT CCA GTG TCT ; LAR1 GAG GGG ATC GAA AAG CTT CCT ; LAF2 
AGG AAG CTT TTC GAT CCC CTC; LAR2 GCG GCC GCG ATC ACG GAG AGT 
GCC TCT GAC AC; RAF1 GCG GCC GCG TGG GCA GGA GCA CTC GCT GT; 
RAR1 GAG TAG GGA ACT AGC GTG GG; RAF2 CCC ACG CTA GTT CCC TAC 
TC; RAR2 GAC CAC CCA GAT GCA AAC AGG; RAF3 CGC ACC TTA TCG ATT 
GCA A; RAR3 GTC GAC CCG ACC AAC AGC CAA ACC CAC CAA). The left arm 
was created by using two primer pairs that produce 1.3 kb and 2.67 kb fragments (LAF1 
to LAR1 and LAF2 to LAR2, respectively) which were ligated using an internal HindIII 
site to obtain the entire 3.97 kb fragment.  The right arm was created using three different 
primer pairs that produce two overlapping fragments of 1.0 kb containing the stop codon 
mutation (RAF1 to RAR1 and RAF2 to RAR2) and 3.0 kb (RAF3 to RAR3) which were 
ligated using an internal ClaI site to obtain the entire 4.0 kb fragment. The 3.97 kb and 
4.0kb fragments were cloned in tandem into the pGEM-5Zf(+) vector (Promega). We 
then inserted a 2.0 kb NotI-NotI cassette containing a floxed neomycin gene (LoxP site - 
PGK promoter - Neo cDNA - LoxP site) and a 2.2 kb SalI-SalI cassette with the 
thymidine kinase gene (PGK promoter - TK cDNA). Vectors containing the Neo and TK 
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cassettes were provided by the Transgenic Animal Modeling Core Facility of the 
University of Massachusetts Medical School. The final targeting vector and intermediate 
constructs were subjected to DNA sequencing before proceeding. 
 
Screening mouse embryonic stem cells for the Runx1
HTY350-352AAA
 allele 
The targeting vector was linearized with AscI and electroporated into PC3 
(129S5/SvEvBrd) embryonic stem (ES) cells (Transgenic Animal Modeling Core 
Facility, University of Massachusetts Medical School) (i.e., 107 ES cells were transfected 
with 20 ug linearized construct at 230 V and 500 uF). Positive selection was started 24 
hours after electroporation by addition of 180 ug/mL of G418 (Invitrogen Life 
Technologies, Inc., Carlsbad, CA). Non-homologous recombination was selected against 
using thymidine kinase. Resistant clones were transferred into and cultured in 96-well 
plates. Homologous recombination of the Runx1HTY350-352AAA allele was established by 
Southern blot analysis using restriction sites and probes external to the targeting vector as 
in Figure 14. Hybridization was carried out using the PerfectHyb Plus Hybridization kit 
(Sigma-Aldrich, St. Louis, MO). Southern blot analysis identified a single clone with a 
correctly targeted mutation of the Runx1 locus. 
 
Generation of the Runx1
HTY350-352AAA
 mice 
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The PC3 ES cell clone with a targeted Runx1HTY350-352AAA allele was micro-injected into 
C57BL/6 blastocysts. Chimeric mice with a significant ES cell contribution (as 
determined by agouti coat color) were mated with wild type C57BL/6 and germ line 
transmission of the mutant allele was determined by Southern blot genotyping of tail 
DNA from offspring and confirmed by PCR (Primers 5’ to 3’: forward ACT CTG GCA 
GTC TAG GAA GCC, reverse AGG CGC CGT AGT ATA GAT GGT A). This PCR 
reaction amplifies a 300 bp fragment including the mutation encoding HTY to AAA; 
CAC ACC TAC to GCC GCG GCA. This creates a new digestion site for SacII which 
cleaves CCGC^GG. After initial screenings by Southern blot analysis, subsequent 
generations were genotyped by PCR and restriction enzyme digest (Figure 21B).   
Runx1HTY350-352AAA heterozygous mice were crossed to generate Runx1HTY350-352AAA 
homozygous mice and offspring were subjected to genotyping by PCR and Southern blot 
analysis.  
 
Immunofluorescence microscopy  
Bone marrow cells were isolated and spun onto glass slides (100,000 cells per slide). 
Cells were fixed using formaldehyde (3.7%), and permeabilized with 0.5% Triton X-100 
for whole-cell preparations. Nuclear matrix-intermediate filament (NMIF) preparations 
were obtained as described.36 Runx1 protein was detected by the AML1(RHD) antibody 
(Oncogene Science, Cambridge, MA; 1:200 dilution) followed by fluorochrome-
conjugated Alexa Fluor 488 secondary antibody (Invitrogen Molecular Probes, Eugene, 
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OR; 1:800 dilution). Lamin A/C was detected with the N-18 antibody (Santa Cruz; 1:800 
dilution) followed by Alexa Fluor 594 (1:800 dilution). Cells were stained with DAPI and 
then mounted in Prolong Gold antifade mounting medium (Invitrogen Molecular Probes). 
Fluorescence images were captured using a Zeiss Axioplan 2 microscope equipped with a 
digital charged-coupled device camera (Hamamatsu Photonics, Bridgewater, NJ Cat. No. 
C4742-95) interfaced with the MetaMorph Imaging System (Universal Imaging 
Corporation Ltd, Marlow, Buckinghamshire, UK). 
 
Colony Forming Unit (CFU) assays and ex vivo culture 
2000 bone marrow cells were plated in duplicate in 35-mm dishes containing Methocult 
methyl cellulose medium (StemCell Technologies Vancouver, BC, Canada Cat. No. 
M3434), incubated at 37°C and colonies were counted by visual inspection on day 7. 
Bone marrow cells cultured ex vivo were in DMEM supplemented with 10% fetal bovine 
serum and L-glutamine but without additional cytokines. If media was supplemented with 
TGF beta, we used a final concentration of 10 ng per ml. When 5-flourouracil (5-FU) was 
used, mice were given IP injections of 150 mg per kg of 5-FU or vehicle (10% DMSO). 
 
Flow cytometry 
Cells were isolated from the bone marrow, spleen, and/or thymus of age matched mice 
into RPMI Medium without phenol red (Invitrogen) with 1mM EDTA, 0.02% sodium 
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azide, and 3% fetal bovine serum. Cells were counted and adjusted to 6x10^7 cells per 
mL for staining. 40 ul of cells was incubated on ice for 20 min with 40 uL of antibody 
cocktails. Antibodies were all purchased from BD Bioscience and were: B220-PE, Gr1-
FITC, CD11b-PE, cKit-APC, Sca1-FITC, CD127-PE-Cy7, CD16/32-v450, CD34-
alexaFlour700, AA4.1-FITC, IgM-PerCP-Cy5.5, CD43-APC, CD3-PE, CD4-PE-Cy7, 
CD8-APC, CD41-FITC, CD71-PE, and Ter119-APC. For lineage exclusion, we used 
antibodies against Ter119, CD3, CD11b, Gr1 and B220 all conjugated to PE. Propidium 
iodide staining was performed by the flow cytometry core facility on cells already stained 
with CD41-FITC and fixed in ethanol. After staining cells were fixed with 1% 
formaldehyde and processed on an LSRII or FACSCalibur machine by the University of 
Massachusetts Flow Cytometry core facility. Analysis of CLP and early B progenitors 
was performed on live cells (stained as above) using a FACS Aria.  
 
qRT-PCR 
RNA was prepared from bone marrow cells using TRIzol following the manufacturer’s 
protocol (Invitrogen).  RNA was treated with DNaseI and 1 µg was subjected to reverse 
transcription with oligo dT primers. Sorted CLP were collected into lysis buffer and RNA 
obtained using an RNAeasy Micro Kit (Quiagen) following the manufacturer’s 
instructions. qRT-PCR was performed on the resulting cDNA using the primer pairs 
listed in Table 7.  
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Table 7: qRT-PCR primers used with Runx1
HTY350-352AAA
 bone marrow 
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Histology 
Soft tissues were fixed in formalin overnight and then embedded in paraffin. Bones for 
marrow sections were fixed in paraformaldehyde for 3 days under vacuum and then 
decalcified for 14 days using 0.5 M EDTA prior to embedding. Six micron sections were 
stained with hematoxylin and eosin by standard procedures.  Embryonic day 12.5 
embryos were dissected from timed pregnancies and placed in PBS. Images were then 
captured using a Axioskop 40 (Carl Zeiss, Inc., Maple Grove, MN) equipped with a 
AxioCam HRc and AxioVision Rel. 4.7 software (Zeiss). 
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Results 
The Runx1
HTY350-352AAA
 homozygous mice bypass embryonic lethality 
To investigate the biological importance of Runx1 interactions with regulatory co-factors 
and the nuclear architecture in vivo, we generated a knock-in mouse model with a Runx1 
missense mutation (Runx1HTY350-352AAA; denoted HTY in figures and tables). This allele 
expresses a protein with a triple point mutation in the domain important for subnuclear 
targeting103 and interaction with several known co-factors, including SMADs.18-
20,134,135,145 Runx1HTY350-352AAA was introduced into the endogenous Runx1 locus by 
homologous recombination (Figure 21A), confirmed by Southern blot analysis and PCR 
assays. An engineered SacII site diagnostic for the HTY to AAA mutation was used to 
discriminate between the amplified PCR products from the wildtype and mutant alleles 
(Figure 21B). Genotyping results revealed that Runx1HTY350-352AAA homozygous mice are 
born at near Mendelian ratios and thus bypass the embryonic day 12.5 lethality associated 
with Runx1 ablation or C-terminal deletion (Figure 21C). Runx1HTY350-352AAA 
homozygous embryos at embryonic day 12.5 were similar to wildtype littermates (Figure 
21D). The weights of adult wildtype and mutant animals were similar at 12 weeks or 12 
months of age (Figure 21E). Runx1 RNA levels in the bone marrow of wildtype and 
mutant animals are equivalent, indicating that the missense mutation does not destabilize 
the mRNA (Figure 21F). Immunofluorescence microscopy of whole cell and NMIF 
preparations of bone marrow cells from wildtype and Runx1HTY350-352AAA homozygous 
mice showed that while both Runx1 proteins are present within the nuclear matrix, 
association of the mutant Runx1 protein with the matrix may be decreased (Figure 21G). 
73 
 
Hence, the Runx1HTY350-352AAA mutation appears to retain essential functions of Runx1 
during embryonic definitive hematopoiesis. Because Runx1 is required throughout 
hematopoiesis, we postulated that this mutation could have effects in hematopoietic 
progenitors or at different stages of hematopoietic lineage progression. 
 
 
 
 
 
 
 
 
Figure 21: Runx1
HTY350-352AAA
 mouse bypasses embryonic lethality. 
(A) Targeting vector for the knock-in mouse contained a floxed Neo cassette as a positive 
selection marker and a TK cassette for negative selection to ensure homologous recombination in 
ES cells. (B) Successful targeting to the native Runx1 locus results in a diagnostic SacII site that 
allows for genotyping by PCR and enzyme digest. From left to right are genotyping results 
showing the change in digest fragment sizes from a wildtype, heterozygous and homozygous 
Runx1HTY350-352AAA mouse.  (C) Runx1HTY350-352AAA animals were born at Mendelian ratios. 
(D) Runx1HTY350-352AAA embryos are healthy at embryonic day 12.5 and are comparable to 
wildtype littermates (3 litters, n=8 WT, 7 HTY). Scale bars are 1mm. (E) Adult wildtype and 
Runx1HTY350-352AAA  mice at 12 weeks or 12 months are equivalent in weight (n=16 WT, 19 
HTY for 12 weeks and 15 WT, 9 HTY for 12 months). (F) qRT-PCR for Runx1 in bone marrow 
cells shows no difference in expression levels (p=0.8 by Student’s T test). Each point represents 
the average of technical replicates from one animal normalized to mCox expression (n=9 WT, 9 
HTY). (G) Whole cell and nuclear matrix-intermediate filament (NMIF) preparations of bone 
marrow from 12 week old wildtype and Runx1HTY350-352AAA animals shows that Runx1 is still 
present within the nuclear matrix. The heterogeneity of the bone marrow preparations 
complicated quantification of Runx1 signal, as endogenous expression levels vary 
widely. Therefore representative Runx1 expressing cells are shown  (n=3 WT, 3 HTY). 
Scale bars are 10 um.  All error bars are SEM. 
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Peripheral blood from Runx1
HTY350-352AAA
 mice reveals subtle hematopoeitic defects 
As part of the initial characterization of the Runx1HTY350-352AAA mice, blood was collected 
for complete blood counts at 8 weeks of age (Table 8). Screening of a large number of 
animals (n=33 wildtype, 26 mutant) revealed subtle, yet consistent and statistically 
significant, alterations. There were no alterations in white blood cells that reached 
statistical significance. However, we observed a significant increase in platelet number 
and size (Table 8, p<0.001 and p=0.012). We also observed a subtle, sub-clinical anemia. 
Absolute red blood cell count was increased, but the cell volume was so much smaller 
that hematocrit was significantly lower than wildtype (Table 8, p=0.025). These 
alterations in the peripheral blood prompted examination of the bone marrow.
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Table 8: Complete blood counts of 8 week old animals 
At 8 weeks of age, peripheral blood samples were collected by retro-orbital bleeds. Complete 
blood counts for 33 wildtype and 26 Runx1HTY350-352AAA homozygous animals are compiled in this 
table with means listed. Errors shown are standard deviation and p values were calculated using 
Student’s T test. 
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The Runx1
HTY350-352AAA
 mutation compromises growth control in bone marrow cells 
Runx1 may help to preserve long-term hematopoietic repopulating capacity by 
maintaining HSC quiescence and appropriate apoptosis.62 Expression of a naturally 
occurring, dominant negative truncated form, Runx1a, in HSC enhanced proliferation and 
increased short-term engraftment.109 To examine hematopoietic progenitor properties in 
the Runx1HTY350-352AAA mice, bone marrow cells from wildtype and homozygous mutant 
animals were isolated and cultured ex vivo. After 7 days in culture, there were 
significantly more cells in cultures from the knock-in animals (Figure 22A, p<0.001). In 
contrast, when the same cells were instead plated in methocellulose for colony forming 
unit (CFU) assays, they formed fewer colonies (Figure 22B, p=0.027). These data 
indicate that Runx1HTY350-352AAA bone marrow cells, while more proliferative, have 
diminished progenitor capacity. The majority of cells taken from day 7 ex vivo cultures 
from both wildtype and Runx1HTY350-352AAA mice express the myeloid lineage antigen 
CD11b (Figure 22C) with very low expression of the B lymphoid B220 or T lymphoid 
CD3 (data not shown). Given the known roles of Runx1 in myeloid and B lymphocyte 
development, these results warranted further investigation of committed populations in 
the Runx1HTY350-352AAA mice. 
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Figure 22: Increased ex vivo growth and diminished colony forming ability of 
Runx1
HTY350-352AAA
 marrow. 
(A) Ex vivo cultures of bone marrow cells from wildtype or Runx1HTY350-352AAA animals (each 
point represents the mean cell number of three technical replicates from one animal; n=3 WT, 5 
HTY). (B) Myeloid colony forming unit assays performed with wildtype or Runx1HTY350-352AAA 
bone marrow cells (n=28 WT, 34 HTY). (C) Cells from the experiment reported in panel A were 
harvested at day 7 and the percentage of cells expressing the myeloid antigen CD11b was 
determined using flow cytometry (n=3 WT, 3 HTY). * p<0.05, *** p<0.001, calculated by 
Student’s T test. All error bars are SEM. 
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TGF beta is involved in maintaining HSC quiescence; however, the exact mechanism is 
poorly understood.146-148 SMAD proteins mediate TGF beta signaling, and Runx1 
interacts with SMAD proteins during hematopoietic development. Therefore, we asked if 
TGF beta signaling is perturbed in the presence of Runx1HTY350-352AAA. Both ex vivo 
growth and CFU assays were repeated with the addition of TGF beta in the medium. 
Growth was suppressed by TGF beta in both wildtype and Runx1HTY350-352AAA cultures, 
but the Runx1HTY350-352AAA cells proliferated more rapidly than wildtype (Figure 22A, 
p=0.024). Similarly, adding TGF beta to the CFU assays suppressed colony forming 
ability, but the difference between wildtype and Runx1HTY350-352AAA marrow was 
maintained (Figure 22B). These data reveal that the mechanism by which TGF beta 
causes quiescence remains intact within the bone marrow of Runx1HTY350-352AAA 
homozygous mice, indicating that TGF beta mediation of quiescence does not signal 
through Runx1. 
 
Figure 23: TGF beta mediated quiescence does not signal through Runx1. 
Ex vivo culture (A) and CFU assays (B) as in Figure 22A and B, but with additional TGF beta to 
a final concentration of 10 ng per mL (error bars are SEM and each point represents mean cell 
number of three technical replicates from one animal; n=3 WT, 5 HTY). As CFU assays in (B) 
used only TGF beta or vehicle treated cells there were insufficient replicates to maintain 
statistical signifigance.  * p<0.05, *** p<0.001, calculated with Student’s T test. 
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Runx1
HTY350-352AAA
 under hematopoietic stress 
Treatment with 5-flourouracil (5-FU) is used to poison transit amplifying cells and 
thereby force repopulation of hematopoietic lineages and mobilize progenitors.149 We 
treated wildtype and Runx1HTY350-352AAA mice with 5-FU and 6 days later analyzed 
peripheral blood with complete blood counts (CBC) and collected bone marrow cells for 
CFU assays. While the overall white blood cell counts after treatment were similar, on 
Day 6 after 5-FU treatment the Runx1HTY350-352AAA mice recovered significantly more 
granulocytes and monocytes than wildtype (Table 9). Also their platelet counts were 
higher, albeit more variable (Table 9). The CBC data implies that Runx1HTY350-352AAA 
bone marrow is able to expand myeloid cells more quickly. CFU assays were performed 
with bone marrow cells from animals treated with vehicle or 5-FU. As expected after 5-
FU treatment, both wildtype and mutant marrow made more colonies than vehicle 
treated. In both vehicle and 5-FU treatment groups the Runx1HTY350-352AAA cells formed 
fewer colonies than wildtype (Figure 24), but the n was not large enough to reach 
statistical significance as in Figure 22B. 
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Table 9: Complete blood counts of peripheral blood after 5-FU treatment 
Peripheral blood was taken from wildtype and Runx1HTY350-352AAA mice 6 days after IP injection 
with 5-FU. Complete blood counts for 11 wildtype and Runx1HTY350-352AAA animals are compiled 
in this table, with means listed. Errors shown are standard deviation and p values were calculated 
using Student’s T test.  
 
 
Figure 24: CFU assays of wildtype and Runx1
HTY350-352AAA
 bone marrow after 5-FU 
treatment 
Wildtype and Runx1HTY350-352AAA homozygous mice were treated with 5-FU or vehicle by IP 
injection. 6 days after injection, bone marrow cells were isolated and used in colony forming unit 
assays. Colonies were counted by visual inspection after 7 days of incubation (n=6 WT, 8 HTY 
for vehicle and 8 WT, 9 HTY for 5-FU). Error bars are SEM.  
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Gene expression analysis of bone marrow of Runx1
HTY350-352AAA
 homozygous mice 
To assess if Runx1HTY350-352AAA was causing dramatic changes in gene expression, bone 
marrow was isolated from wildtype and Runx1HTY350-352AAA homozygous animals for 
qRT-PCR analysis. The majority of genes examined showed no change in expression. 
Runx transcription factors, Cebp transcription factors and the GATA family of 
hematopoietic transcription factors were all unchanged (Figure 25A).  Bmi1 is important 
for self-renewal in hematopoietic cells150,151, SCL is required for long term HSC 
function152,153 and Gfi1 is important for progenitor growth regulation.154,155 These three 
genes also showed similar expression levels (Figure 25A). VpreB1 and Rag1 are 
important in B cell maturation156,157 and their expression levels were down, but not 
enough to maintain statistical significance. However, LCN2 and IRF4 are inflammation 
regulatory genes158-160 that were expressed at significantly lower levels (Figure 25B). 
Expression levels of phenotypic myeloid genes such as Neutrophil Elastase, MPO, 
Csf1R,Gr1 and CD11b was also generally similar, with only the reduction of GM-CSF 
maintaining statistical significance (Figure 25C). The platelet myosin light chain (Myl9) 
is important in platelet function and directly regulated by Runx1.161,162 The gene 
expression of Myl9 was significantly reduced in Runx1HTY350-352AAA marrow (Figure 
25D, p<0.01). In addition, Id1, a transcription factor that can contribute to myeloid 
leukemia163 and is upregulated by the leukemic fusion protein Runx1-ETO164, was 
markedly increased (Figure 25E, p<0.001). These results indicate deregulation of gene 
expression in several hematopoietic lineages. The analysis was performed on total bone 
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marrow and would therefore not be able to detect gene expression changes in a particular 
cell compartment or alterations of genes that are only expressed by a small population of 
cells. The gene expression alterations observed in total bone marrow prompted 
investigation of specific hematopoietic lineages. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: qRT-PCR of bone marrow from Runx1
HTY350-352AAA
 mice 
RNA was isolated from bone marrow cells of 12 week old wildtype and Runx1HTY350-352AAA 
homozygous mice. qRT-PCR was performed to measure expression levels of master phenotypic 
transcription factors and genes important for progenitor growth control (A), genes regulating 
lymphoid development (B), myeloid phenotypic genes  (C), a gene important in platelet function 
(D) and a hematopoietic gene implicated in Runx1-ETO driven malignancy (E). Expression 
levels were normalized to mCox. Each point represents the mean of technical replicates from one 
animal (n=3 to 10). * p<0.05, ** p<0.01, *** p<0.001, calculated by Student’s T test. All error 
bars are SEM. All expression levels are shown relative to mCox. For specific primers please see 
Table 7. 
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The Runx1
HTY350-352AAA
 mutation compromises maintenance of early hematopoietic 
progenitors 
To assess alterations in the earliest progenitor populations, bone marrow from 
Runx1HTY350-352AAA mice was analyzed by flow cytometry. There was a small yet 
statistically significant decrease in the lineage negative, Sca1 positive, c-Kit positive 
population (LSK) which contains HSC, with no significant reductions in the lineage 
negative, Sca1 negative, c-Kit positive (LS-K+) myeloid precursors and lineage negative, 
Sca1 positive, c-Kit negative (LS+K-) lymphoid precursors165 (Figure 26A and B). The 
frequency of common lymphoid progenitor (CLP; Lineage-, IL7Ralpha +, AA4.1+, c-Kit 
intermediate) cells in the Runx1HTY350-352AAA mice was similar to wildtype (Figure 26C 
and D). The LS-K+ compartment contains common myeloid progenitors (CMP), which 
further differentiate into either granulocyte-monocyte progenitors (GMP) or 
megakaryocyte erythroid progenitors (MEP). We determined that these discrete 
populations were not significantly different in Runx1HTY350-352AAA bone marrow when 
compared to wildtype mice (Figure 26E and F).  
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Figure 26: Progenitors in Runx1HTY350-352AAA bone marrow. 
(A) Bone marrow cells from wildtype or Runx1HTY350-352AAA animals were stained using 
antibodies to c-Kit, Sca1, CD16/32, CD34, IL7Ralpha, AA4.1 and Lineage markers (CD3, 
CD11b, B220, Ter119, Gr1) and analyzed by flow cytometry. Lineage negative cells were gated 
and are plotted in panel A to highlight the Lin-Sca1+Kit+ (LSK), myeloid potential L-S-K+ and 
lymphoid potential L-S+K- fractions. (B) Quantification of multiple experiments performed as 
depicted in A, normalizing to the wildtype average of each experiment (n=13 WT, 13 HTY). (C) 
Lineage negative and IL7R alpha positive bone marrow cells were gated and c-Kit versus AA4.1 
was plotted to measure AA4.1+, c-Kit intermediate CLP. (D) Quantification of multiple 
experiments in C (n=6 WT, 6 HTY). (E) Lineage negative, c-Kit positive, Sca1 negative (L-S-
K+) cells from panel A were plotted as CD16/32 versus CD34 to measure the CMP, GMP and 
MEP progenitor populations. (F) Quantification of multiple experiments as in E, normalizing to 
the wildtype average of each experiment (n=10 WT, 10 HTY). * p<0.05, calculated by Student’s 
T test. All error bars are SEM. 
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Deregulation of B and T lymphoid cells with Runx1
HTY350-352AAA
  
We further examined B and T lymphopoiesis in the Runx1HTY350-352AAA mice as Runx1 is 
known to have important biological functions in the maturation of both of these lineages. 
Spleens of the Runx1HTY350-352AAA homozygous animals were significantly enlarged 
(Figure 27A, p=0.019), consistent with the splenomegaly that occurs following 
conditional Runx1 ablation.125 Histological examination of Runx1HTY350-352AAA spleens 
showed deregulation of the white pulp, with decreased delineation of follicles and lower 
cell density (Figure 27B). Bone marrow of Runx1HTY350-352AAA mice exhibited slightly 
increased mature and decreased immature B cell populations (Figure 27C and D, 
p<0.0001 and p<0.001), consistent with a moderate impairment of B-lymphopoiesis. 
Furthermore, there was a decrease in the pre-Pro-B and increase in the Pro-B populations 
(Figure 27E and F, p=0.005 and p=0.04). Taken together, these findings indicate that 
defective Runx1 function from the HTY350-352AAA mutation perturbs B-
lymphopoiesis at multiple stages.  
 
We observed fewer CD8 single positive cells in both the spleen and thymus of 
Runx1HTY350-352AAA animals (Figure 28A and B, p=0.038 and 0.038). The discrete 
populations of CD4/CD8 double negative T cell progenitors within the thymus were not 
altered (Figure 28D and E), nor was thymus size of Runx1HTY350-352AAA animals (Figure 
28C). Our findings indicate that the knock-in mutation does not interfere with early T-
lymphoid development, but alters single positive populations during T cell maturation.  
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Figure 27: B lymphopoiesis in Runx1
HTY350-352AAA
 animals. 
(A) At sacrifice, animals were weighed then the spleen and/or thymus was removed and weighed. 
Displayed is the spleen weight normalized to total animal weight. Each point represents one 
animal (n=14 WT, 15 HTY).  (B) Spleens from 12 month old wildtype or Runx1HTY350-352AAA 
mice were formalin fixed, sectioned and then stained by H & E. Representative fields are shown 
(n=3 WT, 3 HTY). (C) Bone marrow cells from wildtype or Runx1HTY350-352AAA animals were 
stained for B220, IgM, AA4.1 and CD43. B220 positive and IgM positive cells were gated to 
show expression of AA4.1 to separate Immature and Mature B cells. (D) Quantification of 
multiple experiments performed as in C (n=12 WT, 12 HTY). (E) Bone marrow cells from 
wildtype or Runx1HTY350-352AAA animals were stained for B220, IgM, AA4.1, Ly6C, CD49b, 
CD19 and CD43. Cells positive for Ly6C, CD49b and IgM were excluded by gating, and the 
CD43+ B220+ subset is shown to measure AA4.1+ CD19- pre-Pro-B cells and AA4.1+ CD19+  
pro-B cells. (F) Quantification of multiple experiments as in E (n=6 WT, 6 HTY). * p<0.05, ** 
p<0.01, *** p<0.001, calculated by Student’s T test. All error bars are SEM. 
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Figure 28: Altered T lymphopoiesis in Runx1
HTY350-352AAA
 animals 
(A) Spleen or thymus cells were isolated and stained with CD4 and CD8. Cells were gated and 
plotted as CD4 versus CD8 to measure CD4+ and CD8+ T cell populations. (B) Quantification of 
multiple experiments as shown in A (n=12 WT, 14 HTY for both spleen and thymus). (C) 
Displayed is the thymus weight normalized to total animal weight (n=18 WT, 19 HTY). (D) 
Thymus cells were stained with CD4, CD8, CD25 and CD44. CD4 and CD8 double negative 
cells are plotted with CD25 versus CD44 to show the DN1 through DN4 T-Cell progenitor 
populations. (E) Quantification of multiple experiments shown in D (n= 7 WT, 9 HTY).   * 
p<0.05, calculated by Student’s T test. All error bars are SEM. 
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Runx1
HTY350-352AAA
 causes over expansion in both myeloid and megakaryocytic 
lineage cells 
Runx1 mutations are often implicated in myeloid leukemia and Runx1 point mutations 
are associated with familial platelet disorders.77,79,96 Conditional Runx1 ablation in adult 
mice causes defects in myeloid and megakaryocytic lineages.79 Therefore, we anticipated 
the most striking differences in our knock-in mouse would be observed there. We noted a 
significant increase in both the mature granulocyte (CD11b positive, Gr1 high; p<0.0001) 
and immature monocyte / macrophage (CD11b positive, Gr1 intermediate; p<0.0001) 
populations in the spleens of Runx1HTY350-352AAA mice (Figure 29C and D). However, the 
granulocyte population was not significantly different in the bone marrow (Figure 29A 
and B). The expansion in the spleen is consistent with the growth factor independent 
proliferation we observed in murine myeloid cell lines harboring similar mutations.87 The 
expansion also suggests that much of the observed splenomegaly (Figure 27A) may be a 
consequence of myeloid expansion, infiltration and/or accumulation in the spleen, similar 
to that observed in the Runx1 conditional mouse.79  
 
Megakaryocytic maturation is known to be particularly sensitive to Runx1.66 We 
observed that the CD41 positive compartment of both bone marrow and spleen was 
slightly expanded in Runx1HTY350-352AAA mice (Figure 29E and F). This finding was 
unexpected because conditional Runx1 ablation is known to cause 
thrombocytopenia.77,125 Therefore, we next examined the maturation status of the CD41 
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compartment, using propidium iodide staining to assay DNA content in the CD41 
positive cells. This analysis suggests maturation of megakaryocytes is delayed, as shown 
by the marked decrease in 8N and 16N cells compared with the wildtype reference 
(Figure 29G). We confirmed this finding with histological analysis of the bone marrow. 
While some megakaryocytes in the marrow appeared normal, we observed many smaller 
megakaryocytes with less nuclear hematoxylin staining compared with wildtype marrow 
(Figure 29H). These results indicate that Runx1HTY350-352AAA causes a delay in 
megakaryocyte maturation, but the expanded compartment apparently allows the 
homozygous mice to maintain normal, albeit slightly higher, platelet counts (Table 8). 
 
 
 
 
 
Figure 29: Alterations in myeloid compartment and megakaryocytic maturation in 
Runx1
HTY350-352AAA
 animals. 
(A) Bone marrow cells stained with antibodies to Gr1 and CD11b to measure the Gr1 positive 
CD11b positive granulocyte population. (B) Quantification of multiple experiments shown in A 
(n=7 WT, 9 HTY). (C) Spleen cells were stained with antibodies to Gr1 and CD11b to measure 
the Gr1 high, CD11b positive granulocyte and the Gr1 intermediate CD11b positive monocyte / 
macrophage populations. (D) Quantification of multiple experiments performed as shown in A 
(n=7 WT, 9 HTY) (E) Bone marrow or spleen cells were stained for CD41 to measure the 
megakaryocyte population. (F) Quantification of multiple experiments shown in C (n=12 WT, 14 
HTY). (G) Bone marrow cells were stained for CD41, fixed with ethanol and then stained with 
propidium iodide to detect DNA content. Displayed is the CD41 positive fraction, with normal 
hyperploidy of a representative wildtype sample plotted in black, with Runx1HTY350-352AAA  
samples plotted in red to show the reduction in 8N and 16N cells. (H) Histological sections of 
bone marrow from 12 month old wildtype or Runx1HTY350-352AAA mice were H & E stained. 
Megakaryocytes that appear smaller and less hyperploid in the Runx1HTY350-352AAA animals are 
shown. *** p<0.001, calculated by Student’s T test. All error bars are SEM. 
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Red blood cell maturation is perturbed in Runx1
HTY350-352AAA
 homozygous mice 
CBC of Runx1HTY350-352AAA homozygous mice revealed a significantly lower hematocrit 
than wildtype (Table 8, p=0.025). Because the role of Runx1 in erythropoiesis is poorly 
understood, these preliminary results warranted closer examination. 
 
We characterized erythroid progenitor populations using a validated method of flow 
cytometry analysis with the erythroid markers Ter117 and CD71.166,167 Examination of 
bone marrow cells revealed an increase in early erythroid progenitor populations (ProE, 
EryA and EryB) and fewer mature red cell progenitors (EryC) (Figure 30A and C). The 
increase in ProE and EryB progenitors and the decrease in more mature EryC cells were 
all statistically significant (p<0.001, p=0.012 and p<0.01, respectively). In the spleen of 
Runx1HTY350-352AAA mice, ProE cell populations were similar to wildtype, and the increase 
of EryA and EryB with a subsequent decrease in EryC was still observed (Figure 30B 
and D). However, none of the differences in the spleen cells reached statistical 
significance (p=0.14, p= 0.18 and p=0.054 for EryA, EryB and EryC). Additionally, 
qRT-PCR analysis of bone marrow cells showed a significant decrease in the transcript 
levels of hemoglobin beta (p=0.025), with no significant alterations of hemoglobin alpha 
(Figure 30E). Fetal hemoglobin gamma was not significantly increased, inconsistent with 
a delay in globin switching in the mutant mice168 (Figure 30E). Alteration of the alpha 
and beta hemoglobin balance may explain the smaller size of the red blood cells (Table 
8). EPO receptor expression was suppressed in the Runx1HTY350-352AAA marrow, 
consistent with a defect in erythroid progenitors (Figure 30D, p=0.068 due to n=3 WT 
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and 4 HTY). However, neither the levels of the master erythroid transcription factor 
GATA1, nor those of PU.1, a known Runx1 target and direct inhibitor of GATA1, were 
significantly altered (Figure 30D). Thus, the Runx1HTY350-352AAA mutation provides new 
information regarding the role of Runx1 in erythroid development. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30: Altered red blood cell maturation in Runx1
HTY350-352AAA
 animals. 
(A) Bone marrow cells were stained for CD71 and Ter119 and plotted to measure the CD71 
positive, Ter119 intermediate ProE population. Ter119 high cells were plotted CD71 versus 
forward scatter (FSC) to measure the EryA, EryB and EryC progenitor populations. (B) Spleen 
cells were stained and analyzed as in A. (C) Quantification of several experiments shown in A 
(n=12 WT, 14 HTY). (D) Quantification of several experiments shown in B (n=12 WT, 14 HTY). 
(E) qRT-PCR of bone marrow cells for hemoglobin genes (F) qRT-PCR for factors important for 
erythroid maturation and an important antagonist of erythropoiesis. Each point represents the 
average of technical replicates from one animal (n=3 to 11). * p<0.05, ** p<0.01, calculated by 
Student’s T test. All error bars are SEM. 
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Long term effects of Runx1
HTY350-352AAA
 in aged mice 
To investigate long term effects of Runx1HTY350-352AAA on hematopoietic progenitors and 
leukemogenesis, a cohort of wildtype and homozygous knock-in animals was monitored 
until 1 year of age. Peripheral blood was taken regularly for complete blood counts. The 
alterations observed in 8 week old animals (Table 8) generally remained consistent in this 
cohort over 12 months. There remained no difference in white blood cells or their 
differential (Figure 31A). Red blood cell counts and total hemoglobin were similar, but 
there remained lower hematocrit from smaller red blood cells in the Runx1HTY350-352AAA 
mice (Figure 31B). The increased number and size of platelets observed at 8 weeks was 
also maintained over 12 months (Figure 31C). Animals were sacrificed at 12 months of 
age and examined for any hematopoietic neoplasms. We observed one B-cell lymphoma 
and one liver carcinoma with severe steatosis  in the 12 month old Runx1HTY350-352AAA 
mice (Figure 31D and E) with no tumors in age matched wildtype controls (n=22 
wildtype and 15 mutant). These results are similar to Runx1 conditional mice which have 
increased myeloid infiltration of the liver and spleen and with age develop lymphomas.125 
The low tumor frequency is also reminiscent of the conditional knock-in of Runx1-ETO 
which, without additional mutagenesis, causes a low rate of lymphoma in aged mice.169  
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Figure 31: Long term effects of Runx1
HTY350-352AAA
 
A cohort of Runx1HTY350-352AAA mice were aged to 12 months and had blood taken at 2, 3, 4, 6, 8, 
10 and 12 months of age to compare complete blood counts (n=12 WT, 6 HTY). (A) White blood 
cell counts and differentials remained similar. (B) Red blood cell count and hemoglobin were 
similar but their remained a low hematocrit from the smaller red blood cells in Runx1HTY350-352AAA 
mice. (C) Increased number and size of platelets was also maintained. * p<0.05, ** p<0.01, 
***p<0.001 calculated by Student’s T test. Mice were sacrificed at 12 months of age and 
examined for neoplasms. One B-cell lymphoma (D) and one liver carcinoma with severe steatosis 
were observed in Runx1HTY350-352AAA mice with no tumors in wildtype mice (n=22 WT, 15 HTY). 
Shown are paraffin embedded sections stained with hematoxylin and eosin at 40x magnification. 
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Discussion 
Mutations in specific domains of Runx1 that disrupt subnuclear targeting and co-factor 
interactions alter target gene regulation, block differentiation and confer a pre-leukemic 
phenotype.87,128 It was therefore of interest to investigate the functional activities of these 
domains in vivo. We developed and characterized Runx1HTY350-352AAA knock-in mice that 
bypass the embryonic lethality observed with Runx1 ablation or C-terminal truncation.  
When expressed in vivo, this mutant perturbs multiple hematopoietic lineages. Thus, the 
Runx1HTY350-352AAA mutation discriminates specific roles for Runx1 during 
embryogenesis and adult hematopoiesis.10,143 
 
Primary bone marrow cells in homozygous Runx1HTY350-352AAA knock-in mice still retain 
Runx1 signal in the nuclear matrix. While the amount of Runx1 retained in the nuclear 
matrix is likely reduced, the heterogeneous cell population and the relatively low 
endogenous expression levels make quantification difficult. During the initial in vitro 
characterization by our lab of NMTS mutations, we found that even a C-terminal 
truncation could still retain some Runx1 in the matrix by biochemical fractionation. As a 
truncation that completely removes the NMTS does not abolish signal, and with the 
sensitivity of immunofluorescence, it is understandable matrix association can be 
perturbed while some signal is still retained.  
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qRT-PCR of bone marrow cells was able to provide insights about global gene 
deregulation occurring in the presence of Runx1HTY350-352AAA. However, that analysis is 
severely limited by using whole bone marrow. Dramatic changes could be seen, but 
alterations with specific cell populations or in an important gene that is only expressed in 
a small population would be lost in the relatively high background. Sorting specific 
populations by flow cytometry prior to extracting RNA would be very informative, 
especially for genes that appeared to be changing in the whole bone marrow, but were too 
variable to meet statistical significance, such as VpreB1 and MPO. It is likely that their 
expression is being altered, but only in subsets of cells. 
 
Bone marrow progenitor cell growth regulation is perturbed in the Runx1HTY350-352AAA 
homozygous animals, as indicated by increased growth ex vivo, and expansion or 
contraction of progenitor compartments in vivo. These observations are combined with 
the decreased progenitor ability in ex vivo colony formation assays and a reduction of 
LSK cells. Conditional ablation of Runx1 in adult mice causes an increase in LSK cells, 
which are less competitive over time.79,125 The germline mutation likely deregulates 
progenitor growth control very early, and by adulthood it is possible only less 
competitive cells remain, explaining the smaller LSK population with reduced colony 
forming ability. These data suggest that Runx1HTY350-352AAA is compromised in the normal 
roles of Runx1 that maintain control of progenitor growth and proliferation.61   
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The Runx1HTY350-352AAA homozygous mice have splenomegaly, abnormalities in the white 
pulp of the spleen and deregulated B cell maturation. Several cell compartments of the B 
lineage are affected. Pre-Pro-B and Pro-B progenitors are altered in addition to the 
balance of immature and mature circulating B cells. Conditional Runx1 ablation79,125 or 
expression of leukemic fusion proteins that inhibit Runx1 function67 deplete the CLP 
compartment and inhibit B-cell development in its early stages. Runx1HTY350-352AAA 
contrasts by altering the balance of multiple compartments. This implies that this specific 
domain of Runx1 has functional roles at multiple stages of B-lymphopoiesis. Down-
regulation of Runx1 is required during T-cell maturation for silencing of CD4 in 
CD4/CD8 double positive cells.70 A knock-in mouse model that removed the C-terminal 
VWRPY motif decreased the CD8 positive T cell population in the spleen.69 Similarly, 
Runx1HTY350-352AAA homozygous mice have fewer CD8 single positive T-cells in spleen 
and thymus. Thymus size and early T-cell progenitors were not significantly altered in 
Runx1HTY350-352AAA homozygous mice, in contrast to the smaller thymus and 
differentiation block observed after Runx1 excision in adults.79,125 These results define 
contributions of precise domains with the known roles of Runx1 in control of both B and 
T lymphopoiesis.64,65,67,170-173 Taken together, these data suggest that the HTY350-352 
mutation compromises normal physiological functions of Runx1 and consequently 
deregulates B and T-lymphopoiesis.  
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The spleen harbors a major reserve of myeloid cells in healthy mice174 and these cells 
undergo expansion with Runx1 loss.79 We observed significant expansion of both the 
monocyte and granulocyte compartments in Runx1HTY350-352AAA homozygous spleens, 
suggesting that the observed splenomegaly is predominantly caused by aberrant 
expansion of these resident myeloid cells. These data are consistent with known 
contributions of Runx1 mutants to myeloid proliferative disease.51,92 
 
Thrombocytopenia is one of the most common findings in patients with Runx1 
mutations, and in animal models employing conditional Runx1 ablation.77,79 The 
Runx1HTY350-352AAA homozygous mice are defective in megakaryocyte maturation and 
have a slight expansion of CD41 positive cells. Despite perturbed maturation, and unlike 
conditional Runx1 ablation79,125, Runx1HTY350-352AAA homozygous mice are still able to 
maintain platelet counts within normal ranges. Thus Runx1 functions associated with 
HTY350-352 are required for megakaryocytic maturation but do not block platelet 
production. 
 
Abnormalities in primitive erythrocytes from Runx1 null mice and perturbation of 
erythropoiesis by the leukemic fusion Runx1-ETO implicate Runx1 in 
erythropoiesis.119,175 Subtle changes in the characteristics of red blood cells occur with 
Runx1 haploinsufficiency or conditional ablation, but these differences were not 
explored.79,125 Runx1HTY350-352AAA homozygous mice have a lower hematocrit, resulting 
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from smaller red blood cells. A decrease in beta hemoglobin and the presence of alpha 
rich hemoglobin may explain the smaller cell size. In patients with beta thalassemia, the 
alpha rich hemoglobin is less stable and resultant red blood cells have difficulty retaining 
shape.176 Red cell maturation was perturbed in the Runx1HTY350-352AAA homozygous mice, 
causing an increase in the earliest erythroid progenitors, with a subsequent decrease in the 
more mature cells. Thus, Runx1HTY350-352AAA causes a defect in erythroid maturation. 
Runx1 expression normally decreases during erythroid maturation.63 Therefore, it is 
possible that the mechanism is indirect, with Runx1HTY350-352AAA somehow interfering 
with the endogenous downregulation. 
 
Inhibition of Runx1 function does not cause leukemia without additional mutations. Even 
the leukemia associated t(8;21) translocation can be found in healthy individuals.177,178  
With advanced age additional mutations can occur and conditional mice with Runx1 
ablation or knock-in of Runx1-ETO have a low incidence of lymphomas.125,169 The 
Runx1HTY350-352AAA homozygous mice also have a low incidence of tumors, which 
supports the hypothesis that loss of function in C-terminal domain of Runx1 may 
promote leukemogenesis.  
 
Runx factors organize and scaffold regulatory machinery, including factors that support 
chromatin structure and nucleosome organization at strategic sites of target gene 
promoters and in focal nuclear microenvironments.26 Subtle alterations in the scaffolding 
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function of Runx1 could have profound regulatory effects. As the point mutation is 
within the domain important for subnuclear localization, alterations in subnuclear 
organization and/or perturbed protein interactions are likely responsible for the 
hypomorphic hematopoietic phenotypes of the Runx1HTY350-352AAA knock-in mouse.  
 
Our findings reinforce the pivotal role of Runx1 as a master regulator of hematopoiesis. 
Runx1HTY350-352AAA represents a germline Runx1 mutation that bypasses embryonic 
lethality but alters multiple differentiated lineages in the adult. Runx1HTY350-352AAA 
homozygosity results in defective growth control of hematopoietic progenitors, 
deregulation of B-lymphoid and myeloid lineages, as well as maturation delays in 
megakaryocytic and erythroid development. Our study establishes a novel dimension in 
Runx1 mediated regulatory control that separates its roles in HSC emergence and 
differentiation across multiple hematopoietic lineages. 
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Chapter 5: Summary and Conclusions 
Runx1 is a master regulator of hematopoiesis, important in the HSC10,58,60,62,80,179 and 
throughout differentiated hematopoietic lineages.63,79,80,102,119,142 There is some evidence 
for Runx1 function without CBFbeta.180 However, Runx1 is generally thought to always 
act with CBFbeta as a heterodimer. CBFbeta increases DNA-binding ability of Runx1181 
and is expressed during definitive hematopoiesis at stages where Runx1 is known to be 
important.100  Further supporting this concept, there are identical consequences of Runx1 
and CBFbeta ablation10,58,59,99,101,143,182 or inhibition by leukemic fusion proteins183-185 
during embryonic definitive hematopoiesis. 
 
The essential functions of Runx1 in normal hematopoiesis are juxtaposed with frequent 
perturbations of Runx1 in hematopoietic disease.92,95,97,186-188 In many cases, mutations in 
Runx1 correlate with poor prognosis.92,172,188 Combined, Runx1 and CBFbeta are the 
most common targets for mutation and translocation in human leukemia.88 The most 
frequent alteration of CBFbeta is caused by inv(16) which generates a chimeric fusion 
protein CBFbeta-SMMHC that sequesters Runx1 from its normal functional domains.189 
Runx1 mutations associated with leukemia cluster into two groups, either DNA-binding 
mutations or C-terminal frame shifts and truncations.96,190 The majority of leukemia 
associated translocations involving Runx1 retain the DNA binding domain, but replace 
the C-terminus with a chimeric fusion.88 With the common loss of Runx1 C-terminal 
domains in hematopoietic diseases, we postulated that losing the function of these 
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domains could be a common disease mechanism. We developed a panel of mutations to 
test the functions of these domains in vitro, and then developed mouse models to examine 
the consequences of losing Runx1 C-terminal domains on hematopoietic development 
and leukemogenesis in vivo. 
 
In vitro analysis of Runx1 C-terminal mutations highlighted the context dependent nature 
of Runx1 function. The Runx1 C-terminal truncation bound DNA, but otherwise 
appeared to be a functional null. Point mutations disrupting subnuclear targeting were 
more sensitive to cellular context. They suppressed proliferation similar to wildtype 
Runx1, but caused deregulation of gene expression that blocked differentiation in a 
myeloid progenitor cell line. The most striking findings came from gene expression 
analysis of those progenitor cell lines before differentiation was initiated. Genes ontology 
clusters important for differentiating monocytes were suppressed, indicating that 
subnuclear targeting defective Runx1 was making cells less poised for differentiation in 
the absence of extracellular signals. Furthermore, promoters of the suppressed genes were 
not enriched for Runx1 binding motifs. The promoters were instead enriched for binding 
sites of known co-factors, whose direct protein-protein interactions with Runx1 should 
have been preserved. These data indicate a non-DNA-binding role of Runx1 in 
deregulation of those genes and provide strong evidence for Runx1 as a transcription 
factor scaffolding regulatory machinery within nuclear architecture as an additional layer 
of regulatory control.26,27,191 
106 
 
  
We next examined the consequences of replacing endogenous Runx1 in vivo with a C-
terminal truncation, Runx1Q307X. Embryos homozygous for Runx1Q307X died during mid-
gestation from severe central nervous system hemorrhage and a complete lack of 
definitive hematopoiesis. During embryonic hematopoiesis a C-terminal truncation of 
Runx1 that lacks domains responsible for co-factor interactions and subnuclear targeting 
is a phenocopy of a complete Runx1 null.10,143 The functions of the domains lost in 
Runx1Q307X are just as critical during hematopoietic development as the ability of Runx1 
to bind DNA. These results highlight the critical importance of factors organizing with 
the highly complex nuclear architecture to carry out their biological functions.26,27,29,54  
 
To clarify to contribution of specific domains lost in the Runx1Q307X C-terminal 
translocation, we generated another knock-in mouse model, Runx1HTY350-352AAA. Embryos 
homozygous for Runx1HTY350-352AAA bypass embryonic lethality, but have hypomorphic 
Runx1 function as adults. Runx1HTY350-352AAA results in defective growth control of 
hematopoietic progenitors, deregulation of B-lymphoid and myeloid lineages, as well as 
maturation delays in megakaryocytic and erythroid development. These phenotypes are 
likely caused by alterations in subnuclear organization and/or perturbed protein 
interactions. Even subtle alterations in the scaffolding function of Runx1 could have 
profound regulatory effects. 
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A hematopoietic progenitor must continue to proliferate without differentiation of the 
progeny in order to cause leukemia. Runx1-ETO or CBFbeta-SMMHC alone is 
insufficient to cause leukemia in model systems unless there is additional mutagenesis or 
a long latency.169,192 In vitro expression of mSTD Runx1 impedes differentiation and 
Runx1HTY350-352AAA homozygosity in vivo deregulates growth control in early 
hematopoietic progenitors. Similar to Runx1-ETO or CBFbeta-SMMHC, conditional 
ablation of Runx1125 and knock-in of Runx1HTY350-352AAA both cause a mild predisposition 
toward hematopoietic neoplasms with a long latency. Taken together, these data support 
the hypothesis that loss of function in Runx1 C-terminal domains represent a common 
mechanism for progenitor deregulation and potentially contribute to leukemogenesis.   
 
Runx1 is important at many steps throughout definitive hematopoiesis in the embryo and 
adult. Germline and conditional knock-ins of Runx1 lacking DNA-binding ability have 
shown where Runx1 function is essential.10,79,125 However, outside of later T-cell 
maturation,69 little was known about the requirements for specific domains of Runx1 
during hematopoiesis. Removal of the entire C-terminus is a developmental phenocopy of 
the complete Runx1 null,143 and knock-in of Runx1HTY350-352AAA spares embryonic 
hematopoiesis but is hypomorphic in many lineages of adult hematopoiesis (Figure 32). 
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Figure 32: Definitive hematopoiesis with Runx1 mutations 
Germline knockout of DNA-binding ability or knock-in Runx1Q307X blocks emergence of the 
hematopoietic stem cells during embryonic hematopoiesis. Conditional ablation of Runx1 in 
adults or germline knock-in of Runx1HTY350-352AAA has consequences for many hematopoietic 
lineages. 
 
Adapted from Larsson and Karlsson, Oncogene 2005; 24(37):5676-92  
Reproduced with permission   
License Number: 2895470995227 
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It is interesting to note that nuclear matrix association was not abolished in primary bone 
marrow cells of homozygous Runx1HTY350-352AAA mice. Initial in vitro characterization of 
the NMTS mutations showed that C-terminal truncations which completely removed the 
NMTS would retain some signal in the nuclear matrix. The majority of the mutant protein 
would not be retained, and the single or triple point mutations similarly lost most of their 
matrix association. The fact that when expressed at endogenous levels in vivo, 
Runx1HTY350-352AAA is still retained within the nuclear matrix indicates that these residues 
alone are not responsible for full subnuclear targeting. These data are also consistent with 
a knock-in mouse model with the equivalent mutation in Runx2 that our lab has 
developed. Homozygous animals for the Runx2 knock-in are also viable, with a subtle 
hypomorphic phenotype (Yang, et al., manuscript in preparation). Given the 
hypomorphic Runx1 phenotype observed in the Runx1HTY350-352AAA mice, we conclude 
that even mild perturbations of the subnuclear targeting of Runx1 can explain the altered 
Runx1 function throughout adult hematopoiesis. 
 
As DNA-binding ability is retained in all of the C-terminal Runx1 mutations, gene 
deregulation must occur by other means. Runx factors have myriad known co-factors, 
and many have known interaction domains that overlap with the NMTS (Figure 33). 
Runx factors are known to provide a scaffold within the nucleus, organizing co-factors 
and chromatin regions in the highly complex three-dimensional architecture of the 
nucleus and this organization of regulatory machinery is important for biological 
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control.26,27,29,54,110,191 The potential consequences of Runx1 not being able to perform 
these functions far exceed loss of a single co-factor interaction. 
 
As a component of the nuclear architecture and functionally organizing transcriptional 
machinery, Runx1 can regulate genes without binding their promoters. The Runx1 
consensus binding site has a hexamer as its core (TGTGGT) and statistically occurs at a 
high frequency. Therefore, as Runx1 is endogenously expressed at relatively modest 
levels, the Runx binding site is present far more frequently than there would be available 
Runx1 to bind it. The wide spread use of Chip-Seq and next generation sequencing 
technologies have provided tools to examine where Runx1 is acting throughout the 
genome.193,194 Supporting the structural role of Runx proteins, ChipSeq data from our 
group using either Runx1 or Runx2 consistently shows the majority of Runx binding 
events occur outside known promoters (Dobson, et al., Wu, et al., and Trombley et al., 
manuscripts in preparation). Promoters of genes altered by the subnuclear targeting 
defective Runx1 in stable 32D cells lines were enriched with co-factor binding sites and 
not the Runx motif. Therefore, Runx1 mediated regulation of those genes must use its 
structural functions. 
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Figure 33: Schematic of Runx1 and interaction domains of known co-factors 
Schematic of murine Runx1, noting the Runt-homology DNA binding domain (RHD), 
Transactivation Domain, nuclear matrix targeting signal (NMTS), and mutations sites  for 
Runx1Q307X and Runx1HTY350-352AAA knock-in mice. Also shown are mapped protein interaction 
domains for: ALY195, SUV39H1196, AP-1197, CBFbeta198, Cdk6199, FET/TET200, ETS-1117, 
MOZ137, p30019, TLE136, LEF-1201, PAX5202, mSin3A203, MEF204, HDACs20, SMADs134,135,145, 
STAT5205, Cebp alpha116, Foxp3206, and PU.1116. Many additional factors have been shown to 
bind Runx1, but are not shown because the interaction domains have not been defined. 
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Were this work to be continued, flow cytometry for sorting out specific cell populations 
should be the immediate priority. Now that flow cytometry has of multiple lineages has 
shown what maturation stages are affected by Runx1HTY350-352AAA, those populations and 
the maturation stages immediately preceding them can be isolated. Microarray or qRT-
PCR analysis of those cell populations could show the exact genes and pathways 
affected. Microarray analysis would also have the benefit of enabling motif analysis to 
understand what co-factors are mediating affects, in addition to identifying novel genes 
regulated directly, or indirectly, by Runx1. Sorting specific populations would also 
enable specialized functional assays to further dissect the defects observed in each 
lineage. In addition, a relatively homogenous population of primary cells would allow for 
replication of the in situ immunofluorescence and quantification of matrix retention in 
discrete cell populations. It remains a possibility that Runx1HTY350-352AAA may alter 
subnuclear targeting to different degrees among cell types. Chromatin structure and the 
altered expression levels of various co-factors could alter matrix retention and add an 
additional layer of context dependent regulatory control. Other known functions of 
Runx1 are highly context dependent so it stands to reason that subnuclear targeting could 
more affected by Runx1HTY350-352AAA in certain populations. 
 
After establishing that Runx1HTY350-352AAA has a low rate of spontaneous tumors, similar 
to that of conditional knock-in of Runx1-ETO, this tumor predisposition should be 
further investigated. The liver and thymus of Runx1HTY350-352AAA homozygous and age 
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matched wildtype controls should be examined for subclinical hematopoietic neoplasms. 
The increased myeloid infiltration observed in spleen might also be present in the liver, 
as it is with Runx1-ETO knock-in and Runx1 conditional ablation.79,169 Despite the lack 
of alterations in thymus size or double negative thymocyte populations, cellularity within 
the thymus should be examined as it has been in other Runx1 knock-in mutations.69 To 
assess the leukemogeneicity of Runx1HTY350-352AAA a bone marrow transduction model 
could be used to ask if retroviral NRAS expression in Runx1HTY350-352AAA versus wildtype 
marrow would progress to leukemia with a shorter latency. Additional known second hits 
in Runx1-ETO or CBFbeta-SMMHC could be transduced into Runx1HTY350-352AAA 
marrow, or retroviral insertional mutagenesis used to look for novel co-operating genes. 
 
This work supports the role of transcription factors interacting with nuclear architecture 
for greater biological control, and shows how even subtle alterations in that ability could 
have profound effects on gene regulation. Runx1 localizes to distinct nuclear 
microenvironments, and this localization is critical for normal biological function.24,25 
This localization requires a nuclear matrix targeting signal (NMTS) which is lost in many 
leukemic mutations and translocations, representing a potential common disease 
mechanism. In these studies, we show that loss of the NMTS and associated functions 
can in some ways mimic the presence of a leukemic fusion protein, and has in vivo 
consequences throughout definitive hematopoiesis.  
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